# EDGAR Filing Document

**Accession Number:** 0001575295
**File Stem:** 0001477932-23-001322
**Filing Date:** 2023-3
**Character Count:** 251257
**Document Hash:** 412dc309ce8dd4559f7fb16cdddd7e68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-23-001322.hdr.sgml**: 20230306

**ACCESSION NUMBER**: 0001477932-23-001322

**CONFORMED SUBMISSION TYPE**: 10-Q/A

**PUBLIC DOCUMENT COUNT**: 87

**CONFORMED PERIOD OF REPORT**: 20221130

**FILED AS OF DATE**: 20230306

**DATE AS OF CHANGE**: 20230306

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Allied Corp.
- **CENTRAL INDEX KEY:** 0001575295
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-CATALOG & MAIL-ORDER HOUSES [5961]
- **IRS NUMBER:** 331227173
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 10-Q/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-56002
- **FILM NUMBER:** 23707959

**BUSINESS ADDRESS:**
- **STREET 1:** 1405 ST. PAUL ST.
- **STREET 2:** SUITE 201
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1Y 9N2
- **BUSINESS PHONE:** 877-255-4337

**MAIL ADDRESS:**
- **STREET 1:** 1405 ST. PAUL ST.
- **STREET 2:** SUITE 201
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1Y 9N2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COSMO VENTURES INC
- **DATE OF NAME CHANGE:** 20130425

?xml version='1.0' encoding='ASCII'? alid_10qa.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 1**

**FORM 10-Q/A**

**☒** **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended **November 30, 2022**

Commission File Number **<u>000-56002</u>**

---

| |
|:---|
| **ALLIED CORP.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Nevada** | **33-1227173** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**<u>1405 St. Paul St., Suite 201, Kelowna, BC, Canada V1Y 9N2</u>**

(Address of principal executive offices) (Zip Code)

**<u>877-255-4337</u>**

(Registrant's telephone number, including area code)

______________________________________________________________

(Former name, former address and former fiscal year, if changed since last report)

**Securities registered pursuant to Section 12(b) of the Act**

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol(s)** | **Name of each Exchange on which registered** |
| **N/A** | **N/A** | **N/A** |

---

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes&nbsp;&nbsp;&nbsp;&nbsp; ☒ No

As of January 23, 2023, there were 97,038,154 shares of common stock issued and outstanding.

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **[PART I—FINANCIAL INFORMATION](#FS)** | **[PART I—FINANCIAL INFORMATION](#FS)** |  |
| [Item 1.](#FS) | [Financial Statements.](#FS) | 3 |
| [Item 2.](#P1I2) | [Management's Discussion and Analysis of Financial Condition and Results of Operations.](#P1I2) | 51 |
| [Item 3.](#P1I3) | [Quantitative and Qualitative Disclosures About Market Risk.](#P1I3) | 61 |
| [Item 4.](#P1I4) | [Controls and Procedures.](#P1I4) | 61 |
| **[PART II—OTHER INFORMATION](#P2)** | **[PART II—OTHER INFORMATION](#P2)** |  |
| [Item 1.](#P2I1) | [Legal Proceedings.](#P2I1) | 62 |
| [Item 1A.](#P2I1A) | [Risk Factors.](#P2I1A) | 62 |
| [Item 2.](#P2I2) | [Unregistered Sales of Securities and Use of Proceeds.](#P2I2) | 63 |
| [Item 3.](#P2I3) | [Defaults Upon Senior Securities.](#P2I3) | 63 |
| [Item 4.](#P2I4) | [Mining Safety Disclosure.](#P2I4) | 63 |
| [Item 5.](#P2I5) | [Other Information.](#P2I5) | 63 |

---

---

| |
|:---|
| 2 |
| *[Tables of Contents](#TOC)* |

---

**ALLIED CORP.**

**CONSOLIDATED FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
| [Condensed consolidated interim balance sheets at November 30, 2022 (unaudited) and August 31, 2022](#BS) | 4 |
| [Condensed consolidated interim statements of operations and comprehensive loss for the three months ended November 30, 2022 and 2021 (unaudited)](#SO) | 5 |
| [Condensed consolidated interim statements of stockholders' deficit for the three months ended November 30, 2022 and 2021 (unaudited)](#SD) | 6-7 |
| [Condensed consolidated interim statements of cash flows for the three months ended November 30, 2022 and 2021 (unaudited)](#CF) | 8 |
| [Notes to the unaudited condensed consolidated interim financial statements](#NT) | 9 |

---

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Condensed Consolidated Interim Balance Sheets**<br>**(Expressed in US Dollars)**<br>

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **August 31,** <br>**2022** |
|  | **(Unaudited)** | |
| **Assets** |  |  |
| **Current assets** |  |  |
| Cash | $117670 | $96043 |
| Inventory (Note 3) | 1188963 | 998988 |
| Other receivables | 102153 | 121428 |
| Prepaid expenses | 24655 | 25187 |
| Total current assets | 1433441 | 1241646 |
| Deposits and advances (Note 4) | 2854155 | 2869825 |
| Right-of-use assets (Note 7) | 168128 | 189325 |
| Property, plant and equipment (Note 5) | 1397466 | 1444038 |
| Intangible assets (Note 6) | 40959 | 44773 |
| **Total assets** | $**5894149** | $**5789607** |
| **Liabilities**  |  |  |
| **Current liabilities** |  |  |
| Accounts payable and accrued liabilities  | $1744900 | $1607862 |
| Due to related parties (Note 12) | 369640 | 384272 |
| Current portion of lease liabilities (Note 7) | 23515 | 24725 |
| Loans payable (Note 8) | 1673577 | 1555654 |
| Secured convertible notes payable (Note 9) | 3434891 | 3334891 |
| Total current liabilities | 7246523 | 6907404 |
| Lease liabilities, net of current portion (Note 7) | 144613 | 164600 |
| **Total liabilities** | $**7391136** | $**7072004** |
| **Stockholders' deficit** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock – 50,000,000 shares authorized, $0.0001 par value Nil shares issued and outstanding | $- | $- |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock – 300,000,000 shares authorized, $0.0001 par value; 97,038,154 shares issued and outstanding (93,967,594 – par value $0.0001 – August 31, 2022) | 9704 | 9397 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid in capital | 35787734 | 33999090 |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock issuable  |  | 540000 |
| Accumulated deficit | (36242206) | (34932665) |
| Accumulated other comprehensive loss  | (1052219) | (898219) |
| Total stockholders' deficit | (1496987) | (1282397) |
| **Total liabilities and stockholders' deficit** | $**5894149** | $**5789607** |

---

Nature of operations and going concern (Note 1)

Commitments (Note 14)

Subsequent events (Note 19)

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Condensed Consolidated Interim Statements of Operations and Comprehensive Loss**<br>**(Expressed in US dollars)**<br>**(Unaudited)**<br>

---

| | | |
|:---|:---|:---|
|  | **For the Three** <br>**Months Ended November 30, 2022** | **For the Three** <br>**Months Ended November 30, 2021** |
| **Revenues** |  |  |
| Sales | $69625 | $19178 |
| Cost of sales (Note 3) | (25958) | (262917) |
| **Gross margin** | **43667** | **(243739)** |
| **Expenses** |  |  |
| Amortization | 26160 | 13299 |
| Consulting fees (Note 10 and 11) | 846657 | 8948948 |
| Foreign exchange (gain) loss  | (3230) | 143 |
| Interest expense and bank charges | 118742 | 114409 |
| Office and miscellaneous  | 70006 | 302290 |
| Professional fees | 177190 | 243788 |
| Travel | 7441 | 12700 |
| **Operating expenses** | **1242966** | **9635577** |
| **Loss before other items**  | **(1199299)** | **(9879316)** |
| **Other expenses** |  |  |
| Accretion |  | (132033) |
| Interest expense | (83199) | (56732) |
| Loss on debt extinguishment | (27043) | - |
| Total other expenses | (110242) | (188765) |
| **Net loss**  | **(1309541)** | **(10068081)** |
| **Other comprehensive loss** |  |  |
| Foreign currency translation adjustments | (154000) | (51041) |
| **Comprehensive loss** | $**(1463541)** | $**(10119122)** |
| **Basic and diluted loss per share** | $**(0.01)** | $**(0.11)** |
| **Weighted average number of common shares outstanding**  | **96027047** | **88784911** |

---

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Condensed Consolidated Interim Statements of Stockholders' Deficit**<br>**(Expressed in US dollars)**<br>**(Unaudited)** <br>

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common stock** | **Common stock** | **Treasury stock** | **Treasury stock** | | | | | | |
|  | **Number of**<br>**shares** | <br>**Amount** | **Number of**<br>**shares** | <br>**Amount** |<br>**Additional**<br>**paid in**<br>**capital** |<br> **Stock**<br>**issuable** |<br>**Stock** <br>**subscription** <br>**receivable** |<br>**Accumulated** <br>**deficit**  | **Accumulated** <br>**other**<br>**comprehensive** <br>**loss** |<br><br>**Total** |
| **Balance, August 31, 2021** | 79858867 | $7986 | 7073170 | $707 | $18099226 | $929985 | $- | $(19393812) | $(614873) | $(970781) |
| Shares issued from treasury | 7073170 | 707 | (7073170) | (707) | 7957316 |  |  |  |  | 7957316 |
| Shares issued for cash | 4566389 | 456 |  |  | 3426404 | (873735) | (250000) |  |  | 2303125 |
| Share issuance costs |  |  |  |  | (253390) |  |  |  |  | (253390) |
| Shares subscribed |  |  |  |  |  | 85126 |  |  |  | 85126 |
| Shares issued for finders fees | 8000 | 1 |  |  | 5999 |  |  |  |  | 6000 |
| Shares issued in error not yet cancelled | 634667 | 64 |  |  | (64) |  |  |  |  |  |
| Detachable warrants issued with convertible notes payable |  |  |  |  | 120310 |  |  |  |  | 120310 |
| Beneficial conversion feature |  |  |  |  | 80247 |  |  |  |  | 80247 |
| Stock-based compensation |  |  |  |  | 531255 |  |  |  |  | 531255 |
| Comprehensive loss for the period | - | - | - | - | - | - | - | (10068081) | (51041) | (10119122) |
| **Balance, November 30, 2021** | 92141093 | 9214 | - | - | 29967303 | 141376 | (250000) | (29461893) | (665914) | (259914) |

---

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Condensed Consolidated Interim Statements of Stockholders' Deficit**<br>**(Expressed in US dollars)**<br>**(Unaudited)** <br>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common stock** | **Common stock** | | | | | |
|  | **Number of**<br>**shares** | <br>**Amount** |<br>**Additional**<br>**paid in**<br>**capital** | <br><br>**Stock**<br>**issuable** | <br><br>**Accumulated** <br>**deficit**  | **Accumulated** <br>**other**<br>**comprehensive** <br>**loss** | <br><br>**Total** |
| **Balance, August 31, 2022** | 93967594 | $9397 | $33999090 | $540000 | $(34932665) | $(898219) | $(1282397) |
| Shares issued for cash | 2925000 | 292 | 1169708 | (540000) |  |  | 630000 |
| Share issuance costs |  |  | (12792) |  |  |  | (12792) |
| Shares issued to settle debts | 145560 | 15 | 86557 |  |  |  | 86572 |
| Stock-based compensation |  |  | 545171 |  |  |  | 545171 |
| Comprehensive loss for the period | - | - | - | - | (1309541) | (154000) | (1463541) |
| **Balance, November 30, 2022** | 97038154 | 9704 | 35787734 | - | (36242206) | (1502219) | (1496987) |

---

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Condensed Consolidated Interim Statements of Cash Flows**<br>**(Expressed in US dollars)**<br>**(Unaudited)**<br>

---

| | | |
|:---|:---|:---|
|  | **For the Three** <br>**Months Ended November 30, 2022** | **For the Three** <br>**Months Ended November 30, 2021** |
| **Cash provided by (used in):** |  |  |
| **Operating activities** |  |  |
| Net loss for the period | $(1309541) | $(10068081) |
| Adjustment to net loss for the period for non-cash items |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accretion  |  | 132033 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 201122 | 36732 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization  | 26160 | 13299 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory write-down to net realizable value |  | 252639 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss on debt extinguishment | 27043 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation - consulting services  |  | 3531266 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation - bonus shares  |  | 4585425 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation - options | 545171 | 531255 |
| Changes in non-cash working capital balance:  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in other receivables | 7369 | 48315 |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease (increase) in prepaid expenses | 532 | (102998) |
| &nbsp;&nbsp;&nbsp;&nbsp;Decrease in deposits and advances | 10675 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accounts payable and accrued liabilities | 142028 | (403745) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in due to related parties  | 15368 | (234) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in inventory | (261783) | (271859) |
|  | (595856) | (1715953) |
| **Investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchase of property, plant, and equipment | (66210) | (375413) |
|  | (66210) | (375413) |
| **Financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds of convertible notes payable | 100000 | 200000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayment of loans payable |  | (342750) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from the issuance of common stock | 617208 | 2140861 |
|  | 717208 | 1998111 |
| Increase (decrease) in cash | 55142 | (93255) |
| Effect of exchange rate on changes of cash | (33515) | (51041) |
| Cash, beginning of period | 96043 | 419825 |
| Cash, end of period | $117670 | $275529 |
| **Supplemental cash flow disclosures:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes paid |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest paid | - | 147839 |
| Non-cash activities: See Note 17 |  |  |

---

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements.

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**1. Nature of operations, reverse take-over transaction and going concern**

a) Nature of operations

Allied Corp. (the "Company or Allied") was incorporated in the State of Nevada on February 3, 2013. On July 1, 2019, the Company changed its name to Allied Corp. The head office and the registered office of the Company are located at 1405 St. Paul Street, Kelowna BC V1Y 2E4.

The Company's business plan is to discover new medical technologies some of which are cannabis derived to target full scope therapy and support for trauma survivors, military veterans and first responders, however the Company has not begun such operations nor obtained the required permits to begin such operations.

On February 18, 2020, the Company acquired all the issued and outstanding share capital of a Colombian company, Allied Colombia S.A.S ("Allied Colombia"). The assets, liabilities and results of Allied Colombia are consolidated in these financial statements beginning from the February 18, 2020 acquisition date. As at November 30, 2022, Allied Colombia has a licensed cannabis farm in Colombia.

b) Going concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss for the three months ended November 30, 2022 of $1,309,541, has generated minimal revenue and as at November 30, 2022 has a working capital deficit of $5,813,082. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's ability to continue as a going concern is dependent upon the Company's ability to raise sufficient financing to acquire or develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements.

c) COVID-19 impact

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and the related adverse public health developments have adversely affected workforces, economies, and financial markets globally, leading to uncertainty and an economic downturn. Although some product distribution was delayed by COVID-19, management has determined that there has been no significant impact to the Company's operations, however management continues to monitor the situation.

d) Business Risks

While some states in the United States have authorized the use and sale of cannabis, it remains illegal under federal law and the approach to enforcement of U.S. federal laws against cannabis is subject to change. The Company plans to engage in cannabis-related activities in the United States, only if and when cannabis operations are federally legalized.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

On January 4, 2018, the then United States Attorney General Jeff Sessions issued a memorandum to United States district attorneys (the "Sessions Memorandum") which rescinded previous guidance from the United States Department of Justice specific to cannabis enforcement in the United States, including the Cole Memorandum. With the Cole Memorandum rescinded, United States federal prosecutors no longer have guidance relating to the exercise of their discretion in determining whether to prosecute cannabis related violations of United States federal law. Since that time, United States district attorneys have taken no legal action against state law compliant entities, and the Biden administration is generally anticipated to seek federal decriminalization of state legal cannabis activity. Nevertheless, a significant change in the federal government's enforcement policy with respect to current federal laws applicable to cannabis could cause significant financial damage to the Company. The Company may be irreparably harmed by a change in enforcement policies of the federal government depending on the nature of such change.

Given the current illegality of cannabis under United States federal law, the Company's ability to access both public and private capital may be hindered by the fact that certain financial institutions are regulated by the United States federal government and are thus prohibited from providing financing to companies engaged in cannabis related activities. The Company's ability to access public capital markets in the United States is directly hindered as a result. The Company may, however, be able to access public and private capital markets in the United States through institutions which are not regulated by the United States federal government, in Canada, and in many other countries in order to support continuing operations.

**2. Significant accounting policies**

Business Presentation

These unaudited condensed consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), and are expressed in United States dollars. The Company's fiscal year end is August 31.

These interim unaudited financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission ("SEC") Form 10-Q. They do not include all of the information and footnotes required by US GAAP for complete financial statements. Therefore, these interim financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended August 31, 2022, included in the Company's Annual Report on Form 10-K filed with the SEC.

The consolidated financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company's financial position at November 30, 2022, and the results of its operations for the three months ended November 30, 2022, and cash flows for the three months ended November 30, 2022. The results of operations for the period ended November 30, 2022 are not necessarily indicative of the results to be expected for future quarters or the full year.

The significant accounting policies followed are:

a) Principles of consolidation

The consolidated financial statements include accounts of Allied Corp. and its wholly-owned subsidiaries, including AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd. and Allied Colombia. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

b) Cash and cash equivalents

Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within three months when acquired. The Company did not have any cash equivalents as of November 30, 2022 and August 31, 2022.

c) Property, plant and equipment

Property, plant and equipment are stated at cost. The Company depreciates the cost of property, plant and equipment over their estimated useful lives at the following annual rates and methods:

---

| | |
|:---|:---|
| Farm facility and equipment | 1 - 10 years straight-line basis |
| Office and computer equipment | 5 - 10 years straight-line basis |
| Land equipment | 10 years straight-line basis |

---

d) Inventory

Inventory is comprised of raw materials, supplies, vegetative and flowering plants, dried flower, diluted crude and CBD isolates available for sale, and purchased cannabis products.

Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company's estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management's estimates and such differences could be material to the Company's consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows.

e) Intangible assets

Intangible assets include licenses which are being amortized over their estimated useful lives of 10 years. The Company's licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition.

The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.

For long-lived assets, impairment losses are only recorded if the asset's carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

f) Long-lived assets

In accordance with ASC 360, *Property, Plant and Equipment*, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

g) Foreign currency translation and functional currency conversion

Items included in these consolidated financial statements of each of the Company's entities are measured using the currency of the primary economic environment in which the entities operate (the "functional currency").

Prior to September 10, 2019, the Company's functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders' equity under accumulated other comprehensive loss.

The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management's analysis of changes in our organization. The change in functional currency was accounted for prospectively from September 10, 2019 and prior period financial statements were not restated for the change in functional currency.

For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transactions. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains.

The Company assessed the functional currency for Allied Colombia to be the Colombian peso. The functional currency for all other subsidiaries is the U.S. dollar.

h) Share issuance costs

Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.

i) Research and development costs

Research and development costs are expensed as incurred.

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

j) Advertising costs

Advertising costs are expensed as incurred. During the three months ended November 30, 2022, the Company incurred advertising costs of $3,026 (November 30, 2021 – $258,683) which was included as a part of office and miscellaneous expense.

k) Revenue recognition

The Company's revenue is comprised of sales of cannabis products.

The Company's revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company's obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company's product. Certain of the Company's customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized.

Sales of products are for cash or otherwise agreed-upon credit terms. The Company's payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.

l) Net income (loss) per common share

Net income (loss) per share is calculated in accordance with ASC 260, *Earnings per Share*. The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding to the extent the effect would not be antidilutive. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.

m) Income taxes

The Company accounts for income taxes under ASC 740, *Income Taxes*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

n) Related party transactions

Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.

o) Significant accounting estimates and judgments

The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company's ability to continue to as going concern as described in Note 1.

p) Financial instruments

ASC 825, *Financial Instruments*, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 825 prioritizes the inputs into three levels that may be used to measure fair value:

<u>Level 1</u>

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

<u>Level 2</u>

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

<u>Level 3</u>

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The financial instruments consist principally of cash, due from related parties, accounts payable, note payable, and convertible notes payable. The fair value of cash when applicable is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments.

For certain of the Company's financial instruments, including accounts payable, due from related parties, notes and loans payable, the carrying amounts approximate their fair values due to the short maturities.

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions.

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

q) Leases

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable.

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7 – Leases.

r) Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 Derivatives and Hedging to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 Debt with Conversion and Other Options for consideration of any beneficial conversion features. On September 1, 2022 the Company adopted ASU 2020-06 using the modified retrospective method and reviewed and calculated the impact on the outstanding financial instruments as of this adoption date concluding there was no impact.

s) Reverse Acquisitions

<u>Identification of the accounting acquirer</u>

The Company considers factors in ASC 805-10-55-10 through 55-15 in identifying the accounting acquirer. The Company uses the existence of a controlling financial interest to identify the acquirer - the entity that obtains control of the acquiree. Other pertinent facts and circumstances also shall be considered in identifying the acquirer in a business combination effected by exchanging equity interests, including the following: (a) The relative voting rights in the combined entity after the business combination, where the acquirer usually is the combining entity whose owners as a group retain or receive the largest portion of the voting rights in the combined entity taking into consideration the existence of any unusual or special voting arrangements and options, warrants, or convertible securities; (b) the existence of a large minority voting interest in the combined entity if no other owner or organized group of owners has a significant voting interest, and where the acquirer usually is the combining entity whose single owner or organized group of owners holds the largest minority voting interest in the combined entity; (c) the composition of the governing body of the combined entity, where the acquirer usually is the combining entity whose owners have the ability to elect or appoint or to remove a majority of the members of the governing body of the combined entity; (d) the composition of the senior management of the combined entity, where the acquirer usually is the combining entity whose former management dominates the management of the combined entity; and (e) the terms of the exchange of equity interests, where the acquirer usually is the combining entity that pays a premium over the pre-combination fair value of the equity interests of the other combining entity or entities, where the acquirer usually is the combining entity whose relative size (measured in, for example, assets, revenues, or earnings) is significantly larger than that of the other combining entity or entities.

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

Pursuant to ASC Paragraph 805-40-05-2, as one example of a reverse acquisition, a private operating entity may arrange for a public entity to acquire its equity interests in exchange for the equity interests of the public entity. In this situation, the public entity is the legal acquirer because it issued its equity interests, and the private entity is the legal acquiree because its equity interests were acquired. However, application of the guidance in ASC 805-10-55-11 through 55-15 results in identifying: (a) The public entity as the acquiree for accounting purposes (the accounting acquiree); and (b) the private entity as the acquirer for accounting purposes (the accounting acquirer).

<u>Measuring the consideration transferred</u>

Pursuant to ASC 805-40-30-2 and 30-3 in a reverse acquisition, the accounting acquirer usually issues no consideration for the acquiree. Instead, the accounting acquiree usually issues its equity shares to the owners of the accounting acquirer. Accordingly, the acquisition-date fair value of the consideration transferred by the accounting acquirer for its interest in the accounting acquiree is based on the number of equity interests the legal subsidiary would have had to issue to give the owners of the legal parent the same percentage equity interest in the combined entity that results from the reverse acquisition. The fair value of the number of equity interests calculated in that way can be used as the fair value of consideration transferred in exchange for the acquiree. The assets and liabilities of the legal acquiree are measured and recognized in the consolidated financial statements at their pre-combination carrying amounts (see ASC 805-40-45-2(a)).

<u>Presentation of consolidated financial statements post reverse acquisition</u>

Pursuant to ASC 805-40-45-1 and 45-2, consolidated financial statements following a reverse acquisition are issued under the name of the legal parent (accounting acquiree) but described in the notes as a continuation of the financial statements of the legal subsidiary (accounting acquirer), with one adjustment, which is to retroactively adjust the accounting acquirer's legal capital to reflect the legal capital of the accounting acquiree. That adjustment is required to reflect the capital of the legal parent (the accounting acquiree). Comparative information presented in those consolidated financial statements also is retroactively adjusted to reflect the legal capital of the legal parent (accounting acquiree). The consolidated financial statements reflect all of the following: (a) The assets and liabilities of the legal subsidiary (the accounting acquirer) recognized and measured at their pre-combination carrying amounts; (b) the assets and liabilities of the legal parent (the accounting acquiree) recognized and measured in accordance with the guidance in Topic 805 "Business Combinations"; (c) the retained earnings and other equity balances of the legal subsidiary (accounting acquirer) before the business combination; (d) the amount recognized as issued equity interests in the consolidated financial statements determined by adding the issued equity interest of the legal subsidiary (the accounting acquirer) outstanding immediately before the business combination to the fair value of the legal parent (accounting acquiree) determined in accordance with the guidance in this topic applicable to business combinations. However, the equity structure (that is, the number and type of equity interests issued) reflects the equity structure of the legal parent (the accounting acquiree), including the equity interests the legal parent issued to effect the combination.

Accordingly, the equity structure of the legal subsidiary (the accounting acquirer) is restated using the exchange ratio established in the acquisition agreement to reflect the number of shares of the legal parent (the accounting acquiree) issued in the reverse acquisition; and (e) the non-controlling interest's proportionate share of the legal subsidiary's (accounting acquirer's) pre-combination carrying amounts of retained earnings and other equity interests as discussed in ASC 805-40-25-2 and 805-40-30-3.

Pursuant to ASC 805-40-45-4 and 45-5, in calculating the weighted-average number of common shares outstanding (the denominator of the earnings-per-share ("EPS") calculation) during the period in which the reverse acquisition occurs: (a) The number of common shares outstanding from the beginning of that period to the acquisition date shall be computed on the basis of the weighted-average number of common shares of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the acquisition agreement; and (b) the number of common shares outstanding from the acquisition date to the end of that period shall be the actual number of common shares of the legal acquirer (the accounting acquiree) outstanding during that period.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The basic EPS for each comparative period before the acquisition date presented in the consolidated financial statements following a reverse acquisition shall be calculated by dividing (a) by (b): (a) The income of the legal acquiree attributable to common shareholders in each of those periods; and (b) the legal acquiree's historical weighted average number of common shares outstanding multiplied by the exchange ratio established in the acquisition agreement.

As a result of the controlling financial interest of the former stockholders of AMBI, for financial statement reporting purposes, the asset acquisition has been treated as a reverse acquisition with AMBI deemed the accounting acquirer and the Company deemed the accounting acquiree under the acquisition method of accounting in accordance with ASC 805-10-55 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC). The reverse acquisition is deemed a capital transaction and the net assets of AMBI (the accounting acquirer) are carried forward to the Company (the legal acquirer and the reporting entity) at their carrying value before the acquisition. The acquisition process utilizes the capital structure of the Company and the assets and liabilities of AMBI which are recorded at their historical cost. The equity of the Company is the historical equity of AMBI.

These consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, AM Biosciences effective from the date of the reverse take—over transaction on September 10, 2019 and Allied Colombia (from the date of acquisition, February 18, 2020). All intercompany balances and transactions have been eliminated upon consolidation.

t) Recent accounting pronouncements

The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the three months ended November 30, 2022, are of significance or potential significance to the Company.

**3. Inventory**

Inventory is comprised of the following items:

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **August 31,** <br>**2022** |
| Work in progress | $258666 | $326556 |
| Finished goods | 592838 | 383459 |
| Inventory in transit | 337459 | 288973 |
| Total inventory | $1188963 | $998988 |

---

The costs of inventory include but are not limited to labor, utilities, nutrition and irrigation, overhead and the depreciation of manufacturing equipment and production facilities, and amortization of licenses determined at normal capacity. Manufacturing overhead and related expenses include salaries, wages, employee benefits, utilities, maintenance and rent of grow facility. The Company began production in Colombia in late 2020, when the Company obtained approval for its strains of products. During the current period, certain costs were determined based on the actual usage of production space as compared to the normal predetermined operational production of the facility based on capacity as the Company gradually started to grow products and prepared the facility ready. Management determined that during the current period, the Company was operating at 57% of predesigned capacity and as a result 57% of rent, amortization expenses, and certain overhead costs are included in costs of inventory.

During the current period, the Company recorded a $nil (August 30, 2022 - $31,737) write-off of inventory costs for products purchased for resale to reduce inventory to its net realizable value of $1,188,963 (August 30, 2022 - $998,988).

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**4. Deposits and advances**

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **August 31,** <br>**2022** |
| a) Towards the purchase of prefabricated buildings | $2656695 | $2656695 |
| b) Deposit towards a license acquisition | 150000 | 150000 |
| c) Prepayments for construction facility in Colombia | 47460 | 63130 |
| Total deposits and advances | $2854155 | $2869825 |

---

a) In 2019, the Company entered to a modular building purchase agreement to acquire and construct an 8,700 square foot facility to be used as a certified Cannabis Cultivation and extraction facility. At November 30, 2022, Company had deposits of $2,656,695 (August 31, 2022 - $2,656,695) to purchase prefabricated buildings. As of November 30, 2022, the Company had not yet received the buildings and the amounts have been recorded as deposits.

b) At November 30, 2022 and August 31, 2022, the Company had paid $150,000 to acquire a license through an asset purchase agreement as described in Note 20(a). At November 30, 2022, the asset purchase has not closed and the amount paid has been recorded as a deposit.

c) The Company paid certain vendors for the construction of farm facilities in Colombia in advance. As at November 30, 2022, the prepayments totaled $47,460.

**5. Property, plant and equipment**

At November 30, 2022, property, plant and equipment consisted of:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | Construction in <br>process | Farm facility and <br>equipment | Office and computer <br>equipment | Land<br>equipment | Total |
| Cost |  |  |  |  |  |
| August 31, 2022 | $460648 | $1152822 | $21348 | $27150 | $1661968 |
| Additions | 30486 | 31909 | 3687 | 128 | 66210 |
| Transfer | (90276) | 90276 |  |  |  |
| Foreign exchange | (36943) | (45331) | (1886) | (2276) | (86436) |
| November 30, 2022 | $363915 | $1229676 | $23149 | $25002 | $1641742 |
| Accumulated depreciation |  |  |  |  |  |
| August 31, 2022 | $- | $210899 | $4084 | $2947 | $217930 |
| Additions |  | 41244 | 705 | 643 | 42592 |
| Foreign exchange | - | (15621) | (361) | (264) | (16246) |
| November 30, 2022 | $- | $236522 | $4428 | $3326 | $244276 |
| Net book value |  |  |  |  |  |
| August 31, 2022 | $460648 | $941923 | $17264 | $24203 | $1444038 |
| November 30, 2022 | $363915 | $993154 | $18721 | $21676 | $1397466 |

---

As of November 30, 2022 and August 31, 2022, the construction in process has not been in use.

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**6. Intangible assets**

At November 30, 2022, intangible assets consisted of:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Cost <br>$ | Foreign exchange<br>$ | Accumulated amortization <br>$ | Accumulated impairment <br>$ | November 30, 2022 <br>Net carrying value <br>$ | August 31, 2022 <br>Net carrying value <br>$ |
| Cannabis licenses | 5447445 | (470434) | (1134385) | (3801667) | 40959 | 44773 |

---

On February 17, 2020, the Company acquired $5,435,334 of licenses as part of the acquisition of Allied Colombia. The licenses acquired are issued by the Republic of Colombia and include the use of seeds for growing Cannabis, production of derivatives from Cannabis for medicinal and scientific use, cultivation of Cannabis plants, and producer of seeds. The Company recorded amortization of these licenses of $658,836 for the year ended August 31, 2021, of which $158,121 was included in cost of inventory.

Management acquired the licenses with a plan to operate in Colombia and believed the amounts paid for the licenses would be recovered from future operations. The Company has only recently started its operations in Colombia and has limited history on which to base future outcomes from operations including cash flows. Cannabis and hemp are considered to be an emerging industry and Colombia does not yet have a sufficiently established observable legal market in which the Company could sell its Cannabis or hemp flower and CBD or THC extracts. Laws and regulations in Colombia are evolving and there is uncertainty in what will be legally permissible in a future market and what prices and demand there would be in Colombia for the Company's products. At the present, the Company's export activities are regulated and restricted by Colombian law and it is uncertain whether future changes in law would favorably impact the Company's operations. Due to the uncertainty in the timing and amount of future cash flows from operations the Company has written down its licenses to the estimated recoverable amount. During the year ended August 31, 2021, the Company recorded impairment of intangible assets in the amount of $2,687,695.

During the three months ended November 30, 2022, the Company recorded amortization of $2,951 (COP 13,860,163) (2021 - $1,436 (5,499,837 COP)).

**7. Leases**

The Company accounts for leases under ASC 842, *Leases*, which establishes a right-of-use ("ROU") model that requires a lessee to record an ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet.

The Company did not have any leases until the acquisition of Allied Colombia during the year ended August 31, 2020. The acquisition resulted in the addition of $82,398 of operating lease assets and liabilities. During the year ended August 31, 2021, the Company re-measured its lease liabilities under this lease as the criteria was met for additional monthly payment when the Company started production as outlined in the lease agreement, resulting in additional lease liabilities of $70,705.

On August 10, 2021, the Company entered into another lease for additional land in Colombia with monthly payment of $2,647 (COP9,970,675) for 12.5 hectares which is intended for use of outdoor cultivation, resulting in additional lease liabilities of $104,902. The lease is for 5 years, and expires in July 2026. Management has assessed the lease as an operating lease.

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company entered into an agreement to lease the land described in 14(e) with a commencement date of June 1, 2020. The lease requires the Company to make monthly payments of $4,501 (CAD$5,870) per month. The lease is for a 10-year term, expiring on May 31, 2030, with one 10-year renewal option and an option for the Company to purchase the land for approximately $920,000 (CAD$1,200,000). Effective November 1, 2020, the Company terminated the lease. Pursuant to ASC 842-20 upon the termination of the lease, the Company derecognized the lease related asset and liability and included any consideration paid or received upon termination that was not already included in the lease payments in the gain or loss on termination of the lease. After recording the proceeds from the landlord and derecognizing the capitalized building costs as well as the right of use asset and liability, the Company recorded a loss of $65,565 on the termination of the lease.

ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company's incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the ROU asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the ROU asset result in straight-line rent expense over the lease term. For finance leases, interest on the lease liability and the amortization of the ROU asset results in front-loaded expense over the lease term. ROU assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. At November 30, 2022, the Company did not have any finance leases.

At November 30, 2022, the weighted average remaining operating lease term was 6 years and the weighted average discount rate associated with operating leases was 15%.

The components of lease expenses were as follows:

---

| | |
|:---|:---|
| Operating lease cost: | $ |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of right-of-use assets | 5500 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest on lease liabilities | 6618 |
| Total operating lease cost | 12118 |

---

The following table provides supplemental cash flow and other information related to leases for the three months ended November 30, 2022:

---

| | |
|:---|:---|
|  | $ |
| Lease payments | 12118 |

---

Supplemental balance sheet information related to leases as of November 30, 2022 are as below:

---

| | |
|:---|:---|
|  | $— |
| Cost | 282273 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated amortization | (36641) |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange | (77504) |
| Net carrying value at November 30, 2022 | 168128 |

---

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

Future minimum lease payments related to lease obligations are as follows:

---

| | |
|:---|:---|
|  | $— |
| 2023 | 35371 |
| 2024 | 47161 |
| 2025 | 47161 |
| 2026 | 45096 |
| 2027 | 22374 |
| 2028 | 22374 |
| 2029 | 22374 |
| 2030 | 11186 |
| Total minimum lease payments | 253097 |
| Less: amount of lease payments representing effects of discounting | (84969) |
| Present value of future minimum lease payments | 168128 |
| Less: current obligations under leases | (23515) |
| Lease liabilities, net of current portion | 144613 |

---

**8. Loans payable**

a) In June 2020, the Company entered into a financing agreement to finance the buildings described in Note 4(a). Pursuant to the agreement, the Company financed $1,253,772 of the purchase price. The Company paid $71,023 at commencement date on May 29, 2020 and would make six monthly interest payments of $37,613 commencing June 20, 2020 and repay the principal of $1,253,772 on November 20, 2020. The loan was extended after the initial maturity date. On December 27, 2021, the Company entered into an amendment agreement. Pursuant to the amendment, the Company will make 27 monthly payments starting on January 20, 2022. For the first 3 months, the Company will make monthly payments of $37,613. For the remaining 24 months, the Company will make monthly payments of $66,288. If the first 6 monthly payments are made on time, the Company may prepay the unamortized loan balance with a 2% penalty of the remaining balance. During the three months ended November 30, 2022, the Company paid interest in the amount of $nil (2021 - $112,839). As of November 30, 2022, the Company has missed five monthly payments and the balance owing is $1,404,129 (August 31, 2022 - $1,291,290).

b) On December 17, 2021, the Company entered into a financing agreement to finance an equipment purchase. On March 31, 2022, the agreement was amended to remove shipping charges. Pursuant to the amended agreement, the Company financed $295,543 of the purchase price with an interest rate of 8% per annum. The Company will make 21 monthly principal and interest payments of $15,000 and a final payment of $633 in September 2023. During the three months ended November 30, 2022, the Company paid interest in the amount of $nil (2021 - $nil). As of November 30, 2022, the Company has missed nine monthly payments and the balance owing is $269,448 (August 31, 2022 - $264,364).

**9. Secured convertible notes payable** 

The Company has granted each and every of the secured convertible note holders a continuing security interest in, a general lien upon, and a right of set-off against all existing and future assets and property under the terms of a security agreement.

a) On January 23, 2020, the Company issued two convertible notes with principal amounts of $400,000 and $200,000, respectively, with a total face value of $600,000 (the "Notes") and warrants to purchase 240,000 shares of the Company's common stock at $1.25 per share for 1 year. The Notes were issued with an original discount of $12,000, and bear interest at 10% per annum compounded monthly. The notes mature on July 20, 2020 and are convertible into shares of the Company's common stock at any time prior to maturity at a conversion price of $1.25 per share.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company determined that there was no derivative liability associated with the Notes or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion features are indexed to the Company's own stock and are classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion features and warrants do not meet derivative classification.

The relative fair values of the convertible notes and the warrants were $470,467 and $117,533 respectively. The effective conversion price was then determined to be $0.98. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $115,383 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $108,100 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $364,517. The beneficial conversion feature of $115,383, the original issue discount of $12,000 and the relative fair value of the warrants of $108,100 discounted the carrying value of the convertible debt on the date of issue. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method. On June 30, 2020, the Company repaid $200,000 of the $600,000 note which left $200,000 outstanding on each note.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On July 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 5% per annum. The maturity date of the convertible notes was amended to due on demand on or before October 31, 2020. In consideration for extending the maturity date, the Company issued to the convertible note holders 16,000 common shares of the Company and warrants to purchase additional 320,000 common shares of the Company at $1.25 per share expiring October 31, 2021. Each note holder received 8,000 common shares and 160,000 warrants.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

The extended convertible notes had a total carrying value of $400,000. As the common shares and warrants were issued as consideration for extending the convertible notes, the fair value of the common share and warrants of $218,397 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $220,065.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On November 1, 2020, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or before March 31, 2021. In consideration for extending the maturity date, the Company agreed to issue to the convertible note holders 100,000 common shares of the Company. Each note holder received 50,000 common shares.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The extended convertible notes had a total carrying value of $400,000. As the common shares were issued as consideration for extending the convertible notes, the fair value of the common share of $110,000 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $110,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Third Modification:

On March 31, 2021, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or before September 30, 2021. In consideration for extending the maturity date, the Company agreed to issue to the convertible note holders 20,000 common shares of the Company. Each note holder received 10,000 common shares.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

The extended convertible notes had a total carrying value of $400,000. As the common shares were issued as consideration for extending the convertible notes, the fair value of the common share of $20,000 were expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $20,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Fourth Modification:

On October 1, 2021, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or after March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;v. Fifth Modification:

On March 31, 2022, the Company entered into amendments to the convertible notes. Pursuant to the amendments, the convertible notes bear simple interest at 10% per annum. Pursuant to the amendments, the maturity date of the convertible notes was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

During the three months ended November 30, 2022, the Company made interest payment of $nil (2021 - $20,000). As at November 30, 2022, the Company has recorded accrued interest of $20,438, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

b) On September 29, 2020, the Company issued a convertible note with a fair value of $163,341 (the "Note") and warrants to purchase 130,673 shares of the Company's common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after March 27, 2021. The Note was convertible into shares of the Company's common stock at any time prior to March 27, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $85,330 and $78,011 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $85,330 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $78,011 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On March 31, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before September 30, 2021. In consideration for extending the maturity date, the Company issued to the convertible note holder 8,268 common shares of the Company.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-60 was applied. As present value of the cash flows under the new debt instrument differed by more than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was substantially different which resulted in extinguishment accounting.

The extended convertible note had a total carrying value of $163,341. As the common shares were issued as consideration for extending the convertible note, the fair value of the common shares of $8,268 was expensed under extinguishment accounting. The fair value of these costs were included in the calculation of the loss on extinguishment of $8,268.

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Third Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iv. Fourth Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

As at November 30, 2022, the Company has recorded accrued interest of $28,785, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

c) On October 26, 2020, the Company issued a convertible note with a face value of $37,613 (the "Note") and warrants to purchase 30,090 shares of the Company's common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after April 23, 2021. The Note was convertible into shares of the Company's common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $20,176 and $17,437 respectively. The effective conversion price was then determined to be $0.65. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $20,176 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $17,437 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

---

| |
|:---|
| 26 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Third Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $7,883, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

d) On November 11, 2020, the Company issued a convertible note with a face value of $85,937 (the "Note") and warrants to purchase 68,750 shares of the Company's common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after May 9, 2021. The Note was convertible into shares of the Company's common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

---

| |
|:---|
| 27 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The relative fair values of the convertible note and the warrants were $48,258 and $37,679 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $48,258 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $37,679 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On June 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before November 30, 2021 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;iii. Third Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

---

| |
|:---|
| 28 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $17,636, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

e) On December 2, 2020, the Company issued a convertible note with a face value of $600,000 (the "Note") and warrants to purchase 240,000 shares of the Company's common stock at $1.25 per share for 2 years. The Note bears interest at 10% per annum. The Note is due on demand after November 27, 2021. The Note was convertible into shares of the Company's common stock at any time prior to November 27, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $457,436 and $142,564 respectively. The effective conversion price was then determined to be $0.95. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $457,436 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $22,564 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On October 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

---

| |
|:---|
| 29 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $119,671, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

f) On January 7, 2021, the Company issued a convertible note with a face value of $300,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after November 27, 2021. The Note was convertible into shares of the Company's common stock at any time prior to April 23, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification. In addition, it was determined that there was no beneficial conversion feature ("BCF") as the stock price at the issuance date was less than the conversion price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On October 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

---

| |
|:---|
| 30 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $50,082, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

g) On March 26, 2021, the Company issued a convertible note with a face value of $18,000 (the "Note") and warrants to purchase 18,000 shares of the Company's common stock at $0.50 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after September 26, 2021. The Note was convertible into shares of the Company's common stock at any time prior to September 26, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

---

| |
|:---|
| 31 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The relative fair values of the convertible note and the warrants were $10,096 and $7,904 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $4,016 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $7,904 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $6,080. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $3,028, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

---

| |
|:---|
| 32 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

h) On March 26, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note") and warrants to purchase 100,000 shares of the Company's common stock at $0.50 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after September 26, 2021. The Note is convertible into shares of the Company's common stock at any time prior to September 26, 2021 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $56,086 and $43,914 respectively. The effective conversion price was then determined to be $0.70. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $22,314 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $43,914 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $33,772. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

---

| |
|:---|
| 33 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $16,767, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

i) On April 30, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note") and warrants to purchase 100,000 shares of the Company's common stock at $1.00 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after October 31, 2021. The Note is convertible into shares of the Company's common stock at any time prior to October 31, 2021 at a conversion price of $1.00 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $61,493 and $38,507 respectively. The effective conversion price was then determined to be $0.61. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $27,272 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $38,507 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $34,221. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

---

| |
|:---|
| 34 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $15,863, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

j) On April 29, 2021, the Company issued a convertible note with a face value of $180,000 (the "Note") and warrants to purchase 180,000 shares of the Company's common stock at $1.00 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after October 29, 2021. The Note was convertible into shares of the Company's common stock at any time prior to October 29, 2021 at a conversion price of $1.00 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $111,422 and $68,578 respectively. The effective conversion price was then determined to be $0.62. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $46,078 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $68,578 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $65,344. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. The maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration.

---

| |
|:---|
| 35 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $28,504, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

k) On July 25, 2021, the Company issued a convertible note with a face value of $35,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after January 25, 2022. The Note was convertible into shares of the Company's common stock at any time prior to January 25, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification. In addition, it was determined that there was no beneficial conversion feature ("BCF") as the stock price at the issuance date was less than the conversion price.

---

| |
|:---|
| 36 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-50 was applied. As present value of the cash flows under the new debt instrument differed by less than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was not substantially different which resulted in modification accounting.

If a convertible debt instrument is modified or exchanged in a transaction that is not accounted for as an extinguishment, an increase in the fair value of the embedded conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and after the modification or exchange) shall reduce the carrying amount of the debt instrument (increasing a debt discount or reducing a debt premium) with a corresponding increase in additional paid-in capital.

The Company recognized the increase in the fair value of the embedded beneficial conversion feature of $1,090 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $33,910 at November 1, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $4,708, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

l) On July 25, 2021, the Company issued a convertible note with a face value of $15,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after January 25, 2022. The Note was convertible into shares of the Company's common stock at any time prior to January 25, 2022 at a conversion price of $1.25 per share.

---

| |
|:---|
| 37 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification. In addition, it was determined that there was no beneficial conversion feature ("BCF") as the stock price at the issuance date was less than the conversion price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-50 was applied. As present value of the cash flows under the new debt instrument differed by less than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was not substantially different which resulted in modification accounting.

If a convertible debt instrument is modified or exchanged in a transaction that is not accounted for as an extinguishment, an increase in the fair value of the embedded conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and after the modification or exchange) shall reduce the carrying amount of the debt instrument (increasing a debt discount or reducing a debt premium) with a corresponding increase in additional paid-in capital.

The Company recognized the increase in the fair value of the embedded beneficial conversion feature of $467 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $14,533 at November 1, 2021.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $2,018, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

---

| |
|:---|
| 38 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

m) On October 1, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note") and warrants to purchase 100,000 shares of the Company's common stock at $1.25 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after March 31, 2022. The Note was convertible into shares of the Company's common stock at any time prior to March 31, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $40,117 and $59,883 respectively. The effective conversion price was then determined to be $0.40. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $40,117 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $59,883 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i. First Modification:

On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bears simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after March 31, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was not granted. As the creditor has not granted a concession, the guidance contained in ASC 470-50 was applied. As present value of the cash flows under the new debt instrument differed by less than 10% from the present value of the remaining cash flows under the terms of the original debt instrument, it was determined that the debt was not substantially different which resulted in modification accounting.

If a convertible debt instrument is modified or exchanged in a transaction that is not accounted for as an extinguishment, an increase in the fair value of the embedded conversion option (calculated as the difference between the fair value of the embedded conversion option immediately before and after the modification or exchange) shall reduce the carrying amount of the debt instrument (increasing a debt discount or reducing a debt premium) with a corresponding increase in additional paid-in capital.

There was no change in the fair value of the embedded beneficial conversion feature immediately before and after the modification. As a result, the Company did not adjust the carrying amount of $1,546 of the convertible debt at November 1, 2021.

---

| |
|:---|
| 39 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii. Second Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

The Company evaluated the transaction under the guidance found in ASC 470-50 *Modification and Extinguishment*. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $11,617, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

n) On October 25, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note") and warrants to purchase 100,000 shares of the Company's common stock at $1.25 per share for 1 year. The Note bears interest at 10% per annum. The Note is due on demand after March 31, 2022. The Note was convertible into shares of the Company's common stock at any time prior to March 31, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note or warrants under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion feature would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion feature is not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature and warrants do not meet derivative classification.

The relative fair values of the convertible note and the warrants were $39,573 and $60,427 respectively. The effective conversion price was then determined to be $0.40. As the stock price at the issuance date was greater than the effective conversion price, it was determined that there was a beneficial conversion feature ("BCF"). The Company recognized the relative fair value of the BCF of $39,573 and an equivalent discount. The Company then recognized the relative fair value of the warrants of $60,427 as additional-paid-in capital and an equivalent discount that further reduced the carrying value of the convertible debt to $Nil. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

Modification:

On March 31, 2022, the Company entered into amendment to the convertible note. Pursuant to the amendment, the convertible note bear simple interest at 10% per annum. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or after September 30, 2022 for no additional consideration.

---

| |
|:---|
| 40 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company evaluated the transaction under the guidance found in ASC 470-50 Modification and Extinguishment. The Company concluded that the Company is experiencing financial difficulty and that a concession was granted. As the creditor has granted a concession, the guidance contained in ASC 470-60-35 was applied.

As the future undiscounted cash flows are greater than or equal to the net carrying value of the original debt, the carrying amount of the debt at the time of the restructuring was not changed and a new effective interest rate was calculated as the discount rate that equates the present value of the future cash payments specified by the new terms with the carrying amount of the debt. Interest expense will be recognized prospectively such that a constant effective interest rate is applied to the carrying amount of the debt at the beginning of each period between restructuring and maturity, consistent with the interest method.

As at November 30, 2022, the Company has recorded accrued interest of $10,959, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

o) On December 23, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after June 23, 2022. The Note is convertible into shares of the Company's common stock at any time prior to June 23, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification.

It was determined that there was a beneficial conversion feature ("BCF") as the stock price at the issuance date was greater than the effective conversion price. The Company recognized the relative fair value of the BCF of $40,800 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $59,200. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

As at November 30, 2022, the Company has recorded accrued interest of $9,370, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On June 23, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

p) On December 23, 2021, the Company issued a convertible note with a face value of $100,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after June 23, 2022. The Note is convertible into shares of the Company's common stock at any time prior to June 23, 2022 at a conversion price of $1.25 per share.

---

| |
|:---|
| 41 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification.

It was determined that there was a beneficial conversion feature ("BCF") as the stock price at the issuance date was greater than the effective conversion price. The Company recognized the relative fair value of the BCF of $40,800 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $59,200. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

As at November 30, 2022, the Company has recorded accrued interest of $9,370, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On June 23, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

q) On January 11, 2022, the Company issued a convertible note with a face value of $150,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after July 10, 2022. The Note is convertible into shares of the Company's common stock at any time prior to July 10, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification.

It was determined that there was a beneficial conversion feature ("BCF") as the stock price at the issuance date was greater than the effective conversion price. The Company recognized the relative fair value of the BCF of $75,600 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $74,400. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

As at November 30, 2022, the Company has recorded accrued interest of $13,274, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On July 10, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

r) On January 31, 2022, the Company issued a convertible note with a face value of $100,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after July 31, 2022. The Note is convertible into shares of the Company's common stock at any time prior to July 31, 2022 at a conversion price of $1.25 per share.

---

| |
|:---|
| 42 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification.

It was determined that there was a beneficial conversion feature ("BCF") as the stock price at the issuance date was greater than the effective conversion price. The Company recognized the relative fair value of the BCF of $75,600 as additional-paid-in capital and an equivalent discount that reduced the carrying value of the convertible debt to $74,400. The discount is being expensed over the term of the loan to increase the carrying value to the face value of the loan using effective interest rate method.

As at November 30, 2022, the Company has recorded accrued interest of $8,301, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On July 31, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

s) On March 29, 2022, the Company issued a convertible note with a face value of $500,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after September 30, 2022. The Note is convertible into shares of the Company's common stock at any time prior to September 30, 2022 at a conversion price of $1.25 per share.

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification. In addition, it was determined that there was no beneficial conversion feature ("BCF") as the stock price at the issuance date was less than the conversion price.

As at November 30, 2022, the Company has recorded accrued interest of $33,699, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

On September 30, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

t) On June 16, 2022, the Company issued a convertible note with a face value of $250,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after December 16, 2022. The Note is convertible into shares of the Company's common stock at any time prior to December 16, 2022 at a conversion price of $1.25 per share.

---

| |
|:---|
| 43 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company determined that there was no derivative liability associated with the Note under ASC 815-15, *Derivatives and Hedging*. Per ASC 815-10-15-74(a), contracts that are both indexed to its own stock and classified in stockholders' equity in its statement of financial position are not considered to be derivative instruments. The conversion feature is indexed to the Company's own stock and is classified in stockholders' equity in the Company's statement of financial position. As the conversion features would meet the scope exception as described in paragraphs ASC 815-15-74(a), the conversion features are not required to be separated from the host instrument and accounted for separately. As a result, at November 30, 2022, the conversion feature does not meet derivative classification. In addition, it was determined that there was no beneficial conversion feature ("BCF") as the stock price at the issuance date was less than the conversion price.

As at November 30, 2022, the Company has recorded accrued interest of $11,438, which is included in accounts payable and accrued liabilities on the consolidated balance sheets. Subsequently, on December 16, 2022, the Company defaulted on the Note and is in process of amending the maturity date and exercise price.

u) On November 28, 2022, the Company issued a convertible note with a face value of $100,000 (the "Note). The Note bears interest at 10% per annum and is due on demand after June 30, 2023. The Note is convertible into shares of the Company's common stock at any time prior to June 30, 2023 at a conversion price equal to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share.

As at November 30, 2022, the Company has recorded accrued interest of $55, which is included in accounts payable and accrued liabilities on the consolidated balance sheets.

10. Equity

*<u>During the three months ended November 30, 2021:</u>*

On September 2, 2021, the Company issued 2,175,933 common shares at fair value of $2,447,925 on issuance date from treasury to the CFO and COO (Note 12) and 1,900,000 common shares at fair value of $2,137,500 to certain employees of the Company as bonuses for past services, which was expensed as consulting fees.

On September 2, 2021, the Company issued 2,997,237 common shares measured at fair value on issuance date of $3,371,892 from treasury for consulting services related to business development for a 12-month period from the issuance date. As the future benefit of the consulting services to be performed cannot be determined, the entire amount was expensed during the three months ended November 30, 2021.

During the year ended August 31, 2021, the Company re-issued 750,000 shares of common stock with total fair value of $637,500 for consulting services, out of which, $425,000 was expensed as consulting fees during the prior year and $159,374 was expensed during the three months ended November 30, 2021. As at November 30, 2021, $53,126 was deferred compensation included in prepaid expenses on the consolidated balance sheet.

On October 20, 2021, the Company issued 3,853,121 units at $0.75 per unit for proceeds of $2,889,841, of which $865,467 was received during the year ended August 31, 2021, and $250,000 was receivable at November 30, 2021. Each unit consists of one common share of the Company and one warrant to purchase the Company's one common shares at $1.25 for a period of two years. During the three months ended November 30, 2021, the Company received an additional $85,126 in cash for units subscribed at $0.75 per unit. In connection with the financing, the Company incurred brokerage commission fees of $205,735.

On November 5, 2021, the Company issued 705,000 units at $0.75 per unit for proceeds of $528,750. Each unit consists of one common share of the Company and one warrant to purchase the Company's one common shares at $1.25 for a period of two years. In connection with the financing, the Company issued 8,000 shares of common stock with a fair value of $6,000 as a finder's fee and incurred other finders' fees of $41,654.

On November 30, 2021, the Company issued 8,268 shares as consideration for extending the maturity date of a convertible note (Note 9 b)(i).

During the three months ended November 30, 2021, the Company issued 634,667 common shares to certain investors for no consideration by error. The Company is in the process of cancelling the shares.

---

| |
|:---|
| 44 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

At November 30, 2021, the Company had received $141,376 in cash for shares subscriptions and had subscriptions receivable of $250,000 for shares issued.

*<u>During the three months ended November 30, 2022:</u>*

On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022.

On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred finder's fee of $10,000 and share issuance costs of $2,792.

On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606.

On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437.

**11. Related party transactions and balances**

All transactions with related parties have occurred in the normal course of operations and are recorded at the exchange amount which is the amount agreed to by the Company and the related party.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Key management compensation and related party transactions

The Company has identified its directors and certain senior officers as its key management personnel. The compensation costs for key management personnel were as follows:

---

| | | |
|:---|:---|:---|
|  | **November 30, 2022** | **November 30, 2021** |
| Consulting fees and benefits  | $97041 | $91986 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Amounts due to related parties

In the normal course of operations, the company shares certain administrative resources with companies related by common management and directors. The administrative resources and services, which were provided in the normal course of operations, were measured at the exchange. All amounts payable and receivable are non-interest bearing, unsecured and due on demand. The following table summarizes the amounts due to related parties:

---

| | | |
|:---|:---|:---|
|  | **November 30,** <br>**2022** | **August 31,** <br>**2022** |
| CEO and Director | $78817 | $80892 |
| COO and Director | 147177 | 143816 |
| An entity controlled by the CFO  | 39456 | 46387 |
| An entity controlled by a Director  | 44690 | 60677 |
| Director  | 59500 | 52500 |
|  | $369640 | $384272 |

---

As of November 30, 2022, the Company had $369,640 (August 31, 2022 - $384,272) payable to related parties for expenses incurred or expensed paid on behalf of the Company by the parties.

---

| |
|:---|
| 45 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**12. Financial risk factors**

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Credit risk:

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash account. Cash accounts are held with major banks in Canada. The Company has deposited its cash with a bank from which management believes the risk of loss is low.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Liquidity risk:

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company's approach to managing liquidity is to ensure that it will have sufficient liquidity to meet liabilities when due. Accounts payable are due within the current operating period. The Company has a working capital deficit and requires additional financing to meet its current obligations (see Note 1).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) Market risk:

Market risk is the risk that changes in market prices, such as foreign exchange rates, interest rates and equity prices will affect the Company's income or the value of its holdings of financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters, while optimizing the return. The Company is not exposed to market risk.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) Interest rate risk:

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk, from time to time, on its cash balances. Surplus cash, if any, is placed on call with financial institutions and management actively negotiates favorable market related interest rates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) Foreign exchange risk:

Foreign currency risk is limited to the portion of the Company's business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate risk, but manages the risk my minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Canadian dollars:

---

| | |
|:---|:---|
|  | **November 30, 2022** |
| Balance in Canadian dollars: |  |
| Cash and cash equivalents | $20119 |
| Accounts receivable | 5088 |
| Accounts payable and accrued liabilities | (759049) |
| Net exposure | (733842) |
| Balance in US dollars: | $(543264) |

---

A 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company's net loss by approximately $54,326 for the three months ended November 30, 2022 (August 31, 2022 – $53,595).

---

| |
|:---|
| 46 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in Colombian Pesos:

---

| | |
|:---|:---|
|  | **November 30, 2022** |
| Balance in Colombian Pesos: |  |
| Cash and cash equivalents | $497503203 |
| Other receivables | 464905150 |
| Accounts payable and accrued liabilities | (3507701444) |
| Net exposure | (2545290091) |
| Balance in US dollars: | $(527303) |

---

A 10% change in the US dollar to the Colombian Peso exchange rate would impact the Company's net loss by approximately $52,730 for the three months ended November 30, 2022 (August 31, 2022 - $49,281).

**13. Capital management**

The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company, in order to support the business and continue as a going concern. The Company considers capital to be all accounts in equity. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company has a working capital deficit and requires additional capital to finance is future business plans. The Company is not subject to any externally imposed capital requirements.

**14. Commitments** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) As of November 30, 2022, the Company recorded a contingent liability of $547,190 (CAD$700,000) for expenses in connection with Allied Colombia acquisition, which is included in the balance of accounts payable and accrued liabilities on the consolidated balance sheet.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) The Company has entered into leases for farm land in Colombia. See Note 7 for details.

**15. Share purchase warrants** 

The following table summarizes the continuity of share purchase warrants:

---

| | | |
|:---|:---|:---|
|  | Number of <br>warrants | Weighted average exercise price <br>$ |
| Balance, August 31, 2022 | 7704135 | 1.25 |
| Expired | (669513) | 1.25 |
| Balance, November 30, 2022 | 7034622 | 1.25 |

---

---

| |
|:---|
| 47 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

As at November 30, 2022, the following share purchase warrants were outstanding:

---

| | | |
|:---|:---|:---|
| Number of warrants | Exercise <br>price <br>$ | &nbsp;&nbsp;&nbsp;&nbsp;Expiry date |
| 1446666 | 1.25 | June 11, 2023 |
| 50000 | 1.25 | July 17, 2023 |
| 103956 | 1.25 | July 26, 2023 |
| 200000 | 1.25 | August 18, 2023 |
| 775000 | 1.25 | August 28, 2023 |
| 2545999 | 1.25 | October 20, 2023 |
| 905000 | 1.25 | November 6, 2023 |
| 36000 | 1.25 | November 24, 2023 |
| 66667 | 1.25 | January 29, 2024 |
| 66667 | 1.25 | February 7, 2024 |
| 113334 | 1.25 | February 12, 2024 |
| 40000 | 1.25 | February 20, 2024 |
| 300000 | 1.25 | February 21, 2024 |
| 177600 | 1.25 | February 26, 2024 |
| 120000 | 1.25 | February 28, 2024 |
| 20000 | 1.25 | March 7, 2024 |
| 67733 | 1.25 | May 27, 2024 |
| 7034622 |  |  |

---

**16. Stock options**

A summary of the Company's stock option activity is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Number of Options | Weighted Average Exercise Price<br>$ | Weighted Average Remaining <br>Contractual Term | Aggregate Intrinsic Value <br>$ |
| Balance, August 31, 2022 | 6000000 | 0.44 | 3.85 | 144000 |
| Outstanding, November 30, 2022 | 6000000 | 0.44 | 3.60 | - |
| Exercisable, November 30, 2022 | 3350000 | 0.44 | 3.44 | - |

---

During the three months ended November 30, 2022, the Company expensed stock-based compensation of $545,171 (2021 - $531,255) related to stock options that vested during the period as consulting fees on the consolidated statement of operations. At November 30, 2022, there was $1,337,922 of unrecognized compensation costs related to non-vested stock-based compensation arrangements granted under the Plan. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| |
|:---|
| 48 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**17. Non-cash activities**

---

| | | |
|:---|:---|:---|
|  | **For the** <br>**Three Months Ended November 30, 2022** | **For the** <br>**Three Months Ended November 30, 2021** |
| **Non-cash activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares issued to settle debt | 59529 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares issued from treasury for services |  | 7957316 |
| &nbsp;&nbsp;&nbsp;&nbsp;Beneficial conversion feature |  | 80247 |
| &nbsp;&nbsp;&nbsp;&nbsp;Relative fair value of warrants issuable with convertible note | - | 120310 |

---

**18. Segment disclosure**

The Company has two operating segments including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) Allied Colombia, a Colombian based company through which the Company intends to commence commercial production in Colombia. (Allied Colombia)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) Allied Corp. which consists of the rest of the Company's operations. (Allied)

Factors used to identify the Company's reportable segments include the organizational structure of the Company and the financial information available for evaluation by the chief operating decision-maker in making decisions about how to allocate resources and assess performance. The Company's operating segments have been broken out based on similar economic and other qualitative criteria. The Company operates the Allied reporting segment in one geographical area (Canada), and the Allied Colombia reporting segment in one geographical area (Colombia).

Financial statement information by operating segment for the three months ended November 30, 2022 is presented below:

---

| | | | |
|:---|:---|:---|:---|
|  | **Allied**<br>**$** | **Allied**<br>**Colombia**<br>**$** | **Total**<br>**$** |
| Gross margin  | 3799 | 39868 | 43667 |
| Net loss | (1158781) | (150760) | (1309541) |
| Depreciation and amortization | 16621 | 9539 | 26160 |
| Total assets as of November 30, 2022 | 3485759 | 2408390 | 5894149 |

---

Geographic information for the three-month period and as at November 30, 2022 is presented below:

---

| | | |
|:---|:---|:---|
|  | **Gross**<br>**Margin**<br>**$** | **Total**<br>**Assets**<br>**$** |
| Canada | 3799 | 3485759 |
| Colombia | 39868 | 2408390 |
| Total | 43667 | 5894149 |

---

---

| |
|:---|
| 49 |
| *[**Table of Contents**](#FTOC)* |

---

**ALLIED CORP.**<br>**Notes to the unaudited condensed consolidated interim financial statements**<br>**November 30, 2022**<br>**(Expressed in US dollars)**<br>

**19. Subsequent events** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a) On March 30, 2021, the Company entered into an asset purchase agreement ("APA") to acquire two privileged licenses issued by the Nevada Department of Taxation purposed for the cultivation of cannabis (the "Licenses"). In consideration for the licenses, the Company agreed to pay $150,000, issue a $1,350,000 promissory note and assume certain liabilities. At November 30, 2022, the asset purchase has not been closed and the amount paid has been recorded as a deposit (Note 4 (b)).

The promissory note bears interest at the Short Term Applicable Federal Rate of 0.11% per annum and shall be repaid through quarterly payments of a minimum of 50% of the net operating income received in connection with the Nevada cannabis operation associated with the acquired Licenses. All outstanding principal and accrued interest is due two years after issuance of the note.

As of January 23, 2023, the Company has not issued any consideration under the APA, other than the initial deposit of $150,000. The Company has not received any assets outlined in the APA. The asset purchase has not closed.

Concurrent with the APA, the Company entered into a services agreement (the "Services Agreement") and a land lease agreement (the "Lease Agreement") with the seller of the Licenses. Pursuant to the Services agreement the seller of the licenses will provide consulting services to the Company in exchange for the reimbursement of expenses incurred.

Pursuant to the Lease Agreement, the Company leased land in North Las Vegas to accommodate an approximately 9,000 square foot building to be used for the cultivation, marketing or sale of cannabis for a period of 25 years. Lease payments shall commence on the date which the first cannabis plant is planted, and monthly lease payments are as follows:

---

| |
|:---|
| $1,500 per month for the first five years. |
| $1,800 per month for years 6 to 10 of the lease. |
| $2,025 per month for years 11 to 15 of the lease. |
| $2,280 per month for years 16 to 20 of the lease. |
| $2,565 per month for years 21 to 25 of the lease. |

---

In addition, for the term of the lease, the Company shall pay the landlord 50% of the net operating income derived from the cannabis cultivation operation located at the leased premises.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b) On December 1, 2022, the Company issued a secured convertible notes with a face value of $70,000. The notes bear interest at 10% per annum and is due on demand on or after June 30, 2023. The note is convertible into shares of the Company's common stock at any time prior to June 30, 2023 at a conversion price equal to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c) On December 7, 2022, the Company issued a secured convertible notes with a face value of $60,000. The notes bear interest at 10% per annum and is due on demand on or after June 30, 2023. The note is convertible into shares of the Company's common stock at any time prior to June 30, 2023 at a conversion price equal to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d) On December 16, 2022, the Company defaulted on a secured convertible note as described in Note 9 t). The Company is in process of amending the maturity dates and exercise prices of these secured convertible notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e) Subsequent to the three months ended November 30, 2022, the Company received $150,000 for subscriptions to 750,000 shares at $0.20 per share.

---

| |
|:---|
| 50 |
| *[**Table of Contents**](#FTOC)* |

---

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*The following discussion relates to the historical operations and financial statements of Allied Corp. for the three months ended November 30, 2022 and 2021.*

<u>Forward-Looking Statements</u>

The following Management's Discussion and Analysis should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this Quarterly Report. The Management's Discussion and Analysis contains forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect," and the like, and/or future-tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements in this Annual Report. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, without limitation, those specifically addressed under the heading "Risks Factors" in our various filings with the Securities and Exchange Commission. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Annual Report.

The following discussion highlights the Company's results of operations and the principal factors that have affected its consolidated financial condition as well as its liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the Company's consolidated financial condition and results of operations presented herein. The following discussion and analysis are based upon Allied Corp's unaudited financial statements contained in this Current Report on Form 10-Q, which have been prepared in accordance with generally accepted accounting principles in the United States. You should read the discussion and analysis together with such financial statements and the related notes thereto.

**Overview**

Allied Corp. ("Allied" or the "Company") is a Nevada corporation, based in Kelowna, British Columbia, Canada. Allied is an international medical cannabis production company with a mission to address today's medical issues by researching, creating and producing targeted cannabinoid health solutions. Allied uses what it considers to be an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique development of therapeutic products.

References in this periodic report on Form 10-Q to "Allied" or the "Company" may include references to the operations of our subsidiaries AM (Advanced Micro) Biosciences, Inc., Allied Colombia S.A.S., Baleno Ltd., Tactical Relief, LLC, and Allied US Products, LLC. Each of these corporations is a 100% wholly owned subsidiary of Allied and consequentially reports quarterly financials up to a consolidated quarterly submission.

Allied's focus is on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment therewith. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinson's disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1.

Allied's objective is to be a company that controls its own international vertically integrated supply chain or CBD, cannabis, and psilocybin products in order to maximize cash flow and profit margins. Our management team believes that having control over our supply chain should enable us to provide a consistent, rolling-harvest supply to the global cannabis community.

Given the average cost of production in North America being approximately $1.00 to $2.00 per gram, we believe our anticipated significantly lower cash cost of cannabis production based on historical production of our operations and other companies growing raw flowers in Columbia afforded by our Colombian production and cultivation should provide us a competitive advantage.

In addition to what we consider our demonstrated ability to cultivate low-cost, high margin cannabis in Colombia primarily for use in proprietary cannabinoid drug and natural health products for international distribution, we have hemp derived CBD natural health products for sale in the United States, have received commercial approval for sale of medical cannabis being produced in Colombia for export to nations other than the United States, and have initiated human clinical phase I trial for our psilocybin-based pharma products ALID 11, ALID 12 and Psilonex™ which are protected under provisional patent and trademarks in the United States.

---

| |
|:---|
| 51 |
| *[Tables of Contents](#TOC)* |

---

**Effects of COVID-19**

In March 2020, the World Health Organization declared COVID-19 a global pandemic. This contagious disease outbreak and the related adverse public health developments have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. While COVID-19 delayed shipment of some of our products, management has determined that there has been no significant impact to the Company's operations, however management continues to monitor the situation.

**Critical Accounting Policies** 

**Business Presentation**

The unaudited condensed consolidated interim financial statements and related notes in this Quarterly Report on Form 10-Q are presented in accordance with accounting principles generally accepted in the United States of America ("US GAAP"), and are expressed in United States dollars. The Company's fiscal year end is August 31.

The unaudited condensed consolidated interim financial statements have been prepared in accordance with US GAAP for interim financial information and with the instructions to Securities and Exchange Commission ("SEC") Form 10-Q. They do not include all of the information and footnotes required by US GAAP for complete financial statements. Therefore, the unaudited condensed consolidated interim financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended August 31, 2022 included in the Company's Annual Report on Form 10-K filed with the SEC.

The unaudited condensed consolidated interim financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company's financial position at November 30, 2022, and the results of its operations for the three months ended November 30, 2022, and cash flows for the three months ended November 30, 2022. The results of operations for the period ended November 30, 2022 are not necessarily indicative of the results to be expected for future quarters or the full year.

The significant accounting policies followed are:

**Principles of consolidation** 

The consolidated financial statements include accounts of Allied Corp. and its majority owned subsidiaries. Subsidiaries are consolidated from the date of acquisition and control and continue to be consolidated until the date that such control ceases. Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect these returns through its power over the investee. All intercompany balances, income, expenses, and unrealized gains and losses resulting from intercompany transactions are eliminated on consolidation.

**Cash and cash equivalents**

Cash is comprised of cash on hand, cash held in trust accounts and demand deposits. Cash equivalents are short-term, highly liquid investments with maturities within three months when acquired. The Company did not have any cash equivalents as of November 30, 2022 and August 31, 2022.

**Property, plant and equipment**

Property, plant and equipment are stated at cost. The Company depreciates the cost of property, plant and equipment over their estimated useful lives at the following annual rates and methods:

---

| | |
|:---|:---|
| Equipment | 10 years straight-line basis |
| Office and computer equipment | 5 years straight-line basis |
| Land equipment | 10 years straight-line basis |

---

**Inventory**

Inventory is comprised of raw materials, supplies, vegetative and flowering plants, dried flower, diluted crude and CBD isolates available for sale, and purchased cannabis products.

Inventory is stated at the lower of cost or net realizable value, determined using weighted average cost. Net realizable value is defined as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. At the end of each reporting period, the Company performs an assessment of inventory and records write-downs for excess and obsolete inventories based on the Company's estimated forecast of product demand, production requirements, market conditions, regulatory environment, and spoilage. Actual inventory losses may differ from management's estimates and such differences could be material to the Company's consolidated balance sheets, statements of net loss and comprehensive loss and statements of cash flows.

---

| |
|:---|
| 52 |
| *[Tables of Contents](#TOC)* |

---

**Intangible assets**

Intangible assets include licenses which are being amortized over their estimated useful lives of 10 years. The Company's licenses are amortized over their economic or legal life on a straight-line basis, whichever is shorter. The licenses have been amortized from the date of acquisition.

The Company periodically evaluates the reasonableness of the useful lives of these assets. Once these assets are fully amortized, they are removed from the accounts. These assets are reviewed for impairment or obsolescence when events or changes in circumstances indicate that the carrying amount may not be recoverable. If impaired, intangible assets are written down to fair value based on discounted cash flows or other valuation techniques. The Company has no intangibles with indefinite lives.

For long-lived assets, impairment losses are only recorded if the asset's carrying amount is not recoverable through its undiscounted, probability-weighted future cash flows. The Company measures the impairment loss based on the difference between the carrying amount and the estimated fair value. When an impairment exists, the related assets are written down to fair value.

**Long-lived assets** 

In accordance with ASC 360, Property, Plant and Equipment, the Company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

**Foreign currency translation and functional currency conversion**

Items included in the consolidated financial statements of each of the Company's entities are measured using the currency of the primary economic environment in which the entities operate (the "functional currency").

Prior to September 10, 2019, the Company's functional currency was the Canadian dollar. Translation gains and losses from the application of the U.S. dollar as the reporting currency during the period that the Canadian dollar was the functional currency are included as part of cumulative currency translation adjustment, which is reported as a component of shareholders' equity under accumulated other comprehensive loss.

The Company re-assessed its functional currency and determined as at September 10, 2019, its functional currency changed from the Canadian dollar to the U.S. dollar based on management's analysis of changes in our organization. The change in functional currency was accounted for prospectively from September 10, 2019 and prior period financial statements were not restated for the change in functional currency.

For periods commencing September 10, 2019, monetary assets and liabilities denominated in foreign currencies are translated into U.S. dollars using exchange rates in effect at the balance sheet date. Opening balances related to non-monetary assets and liabilities are based on prior period translated amounts, and non-monetary assets and non-monetary liabilities incurred after September 10, 2019 are translated at the approximate exchange rate prevailing at the date of the transaction. Revenue and expense transactions are translated at the approximate exchange rate in effect at the time of the transactions. Foreign exchange gains and losses are included in the statement of operations and comprehensive loss as foreign exchange gains.

The Company assessed the functional currency for Allied Colombia to be the Colombian peso. The functional currency for all other subsidiaries is the U.S. dollar.

**Share issuance costs**

Costs directly attributable to the raising of capital are charged against the related share capital. Costs related to shares not yet issued are recorded as deferred share issuance costs. These costs are deferred until the issuance of the shares to which the costs relate, at which time the costs will be charged against the related share capital or charged to operations if the shares are not issued.

**Research and development costs** 

Research and development costs are expensed as incurred.

---

| |
|:---|
| 53 |
| *[Tables of Contents](#TOC)* |

---

**Advertising costs** 

Advertising costs are expensed as incurred.

**Revenue recognition**

The Company's revenue is comprised of sales of cannabis products.

The Company's revenue-generating activities have a single performance obligation and revenue is recognized at the point in time when control of the product transfers and the Company's obligations have been fulfilled. This generally occurs when the product is shipped or delivered to the customer, depending upon the method of distribution and shipping terms set forth in the customer contract. Revenue is measured as the amount of consideration the Company expects to receive in exchange for the sale of the Company's product. Certain of the Company's customer contracts may provide the customer with a right of return. In certain circumstances the Company may also provide a retrospective price adjustment to a customer. These items give rise to variable consideration, which is recognized as a reduction of the transaction price based upon the expected amounts of the product returns and price adjustments at the time revenue for the corresponding product sale is recognized. The determination of the reduction of the transaction price for variable consideration requires that the Company make certain estimates and assumptions that affect the timing and amounts of revenue recognized.

Sales of products are for cash or otherwise agreed-upon credit terms. The Company's payment terms vary by location and customer; however, the time period between when revenue is recognized and when payment is due is not significant. The Company estimates and reserves for its bad debt exposure based on its experience with past due accounts and collectability, write-off history, the aging of accounts receivable and an analysis of customer data.

**Net income (loss) per common share**

Net income (loss) per share is calculated in accordance with ASC 260, Earnings per Share. The weighted-average number of common shares outstanding during each period is used to compute basic earning or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding to the extent the effect would not be antidilutive. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding.

**Income taxes**

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

**Related party transactions**

Related parties are any entities or individuals that, through employment, ownership or other means, possess the ability to direct or cause the direction of the management and policies of the Company. The Company discloses related party transactions that are outside of normal compensatory agreements, such as salaries. Related party transactions are measured at the exchange amounts.

**Significant accounting estimates and judgments**

The preparation of the financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Although management uses historical experience and its best knowledge of the amount, events or actions to for the basis for judgments and estimates, actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and further periods if the review affects both current and future periods.

Significant estimates and assumptions included in these financial statements relate to the valuation assumptions related to the estimated useful lives and recoverability of long-lived assets, stock-based compensation, and deferred income tax assets and liabilities. Judgments are required in the assessment of the Company's ability to continue to as going concern.

---

| |
|:---|
| 54 |
| *[Tables of Contents](#TOC)* |

---

**Financial instruments**

ASC 825, Financial Instruments, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument's categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 825 prioritizes the inputs into three levels that may be used to measure fair value:

*Level 1*

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

*Level 2*

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

*Level 3*

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The financial instruments consist principally of cash, due from related parties, accounts payable, note payable, and convertible notes payable. The fair value of cash when applicable is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of all other financial instruments which are categorized as loans and receivables approximate their current fair values because of their nature and respective relatively short maturity dates or current market rates of interest for similar instruments.

For certain of the Company's financial instruments, including accounts payable, due from related parties, notes and loans payable, the carrying amounts approximate their fair values due to the short maturities.

The Company does not have any assets or liabilities measured at fair value on a recurring basis presented on the Company's balance sheet as of November 30, 2022 and August 31, 2022 other than cash.

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash. The Company limits its exposure to credit loss by placing its cash with high credit quality financial institutions.

**Leases**

The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. The Company uses the implicit interest rate in the lease when readily determinable.

Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability.

**Embedded Conversion Features**

The Company evaluates embedded conversion features within convertible debt under ASC 815 Derivatives and Hedging to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 Debt with Conversion and Other Options for consideration of any beneficial conversion features. On September 1, 2022 the Company adopted ASU 2020-06 using the modified retrospective method and reviewed and calculated the impact on the outstanding financial instruments as of this adoption date concluding there was no impact.

---

| |
|:---|
| 55 |
| *[Tables of Contents](#TOC)* |

---

**Reverse Acquisitions**

*Identification of the accounting acquirer*

The Company considers factors in ASC 805-10-55-10 through 55-15 in identifying the accounting acquirer. The Company uses the existence of a controlling financial interest to identify the acquirer - the entity that obtains control of the acquiree. Other pertinent facts and circumstances also shall be considered in identifying the acquirer in a business combination effected by exchanging equity interests, including the following: (a) The relative voting rights in the combined entity after the business combination, where the acquirer usually is the combining entity whose owners as a group retain or receive the largest portion of the voting rights in the combined entity taking into consideration the existence of any unusual or special voting arrangements and options, warrants, or convertible securities; (b) the existence of a large minority voting interest in the combined entity if no other owner or organized group of owners has a significant voting interest, and where the acquirer usually is the combining entity whose single owner or organized group of owners holds the largest minority voting interest in the combined entity; (c) the composition of the governing body of the combined entity, where the acquirer usually is the combining entity whose owners have the ability to elect or appoint or to remove a majority of the members of the governing body of the combined entity; (d) the composition of the senior management of the combined entity, where the acquirer usually is the combining entity whose former management dominates the management of the combined entity; and (e) the terms of the exchange of equity interests, where the acquirer usually is the combining entity that pays a premium over the pre-combination fair value of the equity interests of the other combining entity or entities, where the acquirer usually is the combining entity whose relative size (measured in, for example, assets, revenues, or earnings) is significantly larger than that of the other combining entity or entities.

Pursuant to ASC Paragraph 805-40-05-2, as one example of a reverse acquisition, a private operating entity may arrange for a public entity to acquire its equity interests in exchange for the equity interests of the public entity. In this situation, the public entity is the legal acquirer because it issued its equity interests, and the private entity is the legal acquiree because its equity interests were acquired. However, application of the guidance in ASC 805-10-55-11 through 55-15 results in identifying: (a) The public entity as the acquiree for accounting purposes (the accounting acquiree); and (b) the private entity as the acquirer for accounting purposes (the accounting acquirer).

*Measuring the consideration transferred*

Pursuant to ASC 805-40-30-2 and 30-3 in a reverse acquisition, the accounting acquirer usually issues no consideration for the acquiree. Instead, the accounting acquiree usually issues its equity shares to the owners of the accounting acquirer. Accordingly, the acquisition-date fair value of the consideration transferred by the accounting acquirer for its interest in the accounting acquiree is based on the number of equity interests the legal subsidiary would have had to issue to give the owners of the legal parent the same percentage equity interest in the combined entity that results from the reverse acquisition. The fair value of the number of equity interests calculated in that way can be used as the fair value of consideration transferred in exchange for the acquiree. The assets and liabilities of the legal acquiree are measured and recognized in the consolidated financial statements at their pre-combination carrying amounts (see ASC 805-40-45-2(a)).

*Presentation of consolidated financial statements post reverse acquisition*

Pursuant to ASC 805-40-45-1 and 45-2, consolidated financial statements following a reverse acquisition are issued under the name of the legal parent (accounting acquiree) but described in the notes as a continuation of the financial statements of the legal subsidiary (accounting acquirer), with one adjustment, which is to retroactively adjust the accounting acquirer's legal capital to reflect the legal capital of the accounting acquiree. That adjustment is required to reflect the capital of the legal parent (the accounting acquiree). Comparative information presented in those consolidated financial statements also is retroactively adjusted to reflect the legal capital of the legal parent (accounting acquiree). The consolidated financial statements reflect all of the following: (a) The assets and liabilities of the legal subsidiary (the accounting acquirer) recognized and measured at their pre-combination carrying amounts; (b) the assets and liabilities of the legal parent (the accounting acquiree) recognized and measured in accordance with the guidance in Topic 805 "Business Combinations"; (c) the retained earnings and other equity balances of the legal subsidiary (accounting acquirer) before the business combination; (d) the amount recognized as issued equity interests in the consolidated financial statements determined by adding the issued equity interest of the legal subsidiary (the accounting acquirer) outstanding immediately before the business combination to the fair value of the legal parent (accounting acquiree) determined in accordance with the guidance in this topic applicable to business combinations. However, the equity structure (that is, the number and type of equity interests issued) reflects the equity structure of the legal parent (the accounting acquiree), including the equity interests the legal parent issued to effect the combination.

Accordingly, the equity structure of the legal subsidiary (the accounting acquirer) is restated using the exchange ratio established in the acquisition agreement to reflect the number of shares of the legal parent (the accounting acquiree) issued in the reverse acquisition; and (e) the non-controlling interest's proportionate share of the legal subsidiary's (accounting acquirer's) pre-combination carrying amounts of retained earnings and other equity interests as discussed in ASC 805-40-25-2 and 805-40-30-3.

---

| |
|:---|
| 56 |
| *[Tables of Contents](#TOC)* |

---

Pursuant to ASC 805-40-45-4 and 45-5, in calculating the weighted-average number of common shares outstanding (the denominator of the earnings-per-share ("EPS") calculation) during the period in which the reverse acquisition occurs: (a) The number of common shares outstanding from the beginning of that period to the acquisition date shall be computed on the basis of the weighted-average number of common shares of the legal acquiree (accounting acquirer) outstanding during the period multiplied by the exchange ratio established in the merger agreement; and (b) the number of common shares outstanding from the acquisition date to the end of that period shall be the actual number of common shares of the legal acquirer (the accounting acquiree) outstanding during that period.

The basic EPS for each comparative period before the acquisition date presented in the consolidated financial statements following a reverse acquisition shall be calculated by dividing (a) by (b): (a) The income of the legal acquiree attributable to common shareholders in each of those periods; and (b) the legal acquiree's historical weighted average number of common shares outstanding multiplied by the exchange ratio established in the acquisition agreement.

As a result of the controlling financial interest of the former stockholders of AMBI, for financial statement reporting purposes, the asset acquisition has been treated as a reverse acquisition with AMBI deemed the accounting acquirer and the Company deemed the accounting acquiree under the acquisition method of accounting in accordance with ASC 805-10-55 of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC). The reverse acquisition is deemed a capital transaction and the net assets of AMBI (the accounting acquirer) are carried forward to the Company (the legal acquirer and the reporting entity) at their carrying value before the acquisition. The acquisition process utilizes the capital structure of the Company and the assets and liabilities of AMBI which are recorded at their historical cost. The equity of the Company is the historical equity of AMBI.

These consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries, AM Biosciences effective from the date of the reverse take—over transaction on September 10, 2019 and Allied Colombia (from the date of acquisition, February 18, 2020). All intercompany balances and transactions have been eliminated upon consolidation.

**Recent accounting pronouncements**

The Company does not expect that recent accounting pronouncements or changes in accounting pronouncements during the three months ended November 30, 2022, are of significance or potential significance to the Company.

**<u>Financial Condition and Results of Operations</u>**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss for the three months ended November 30, 2022 of $1,315,436, has generated minimal revenue and as at November 30, 2022 has a working capital deficit of $5,818,977. These factors raise substantial doubt regarding the Company's ability to continue as a going concern. The Company's ability to continue as a going concern is dependent upon the Company's ability to raise sufficient financing to acquire or develop a profitable business. Management intends on financing its operations and future development activities largely from the sale of equity securities with some additional funding from other traditional financing sources, including related party loans until such time that funds provided by future planned operations are sufficient to fund working capital requirements.

**Results of Operations**

***Comparison of Unaudited Results for the Three Months Ended November 30, 2022 compared to the Three Months Ended November 30, 2021***

*Sales* 

For the three-month period ended November 30, 2022, we had $69,625 in revenue compared to $19,178 for the three-month period ended November 30, 2021. This reflects an increase in the sale of our cannabis flower products as part of our current plan for growth and revenues.

*Gross margin*

For the three-month period ended November 30, 2022, the Company had a gross margin of $43,667 compared to a negative gross margin of $243,739 for the three-month period ended November 30, 2021. The negative gross margin was due to an inventory write-off of 252,639 for the three-month period ended November 30, 2021.

---

| |
|:---|
| 57 |
| *[Tables of Contents](#TOC)* |

---

*Expenses*

For the three-month period ended November 30, 2022, we had total expenses of $1,239,916, compared to total expenses of $10,048,903 for the three-month period ended November 30, 2021. Of the total expenses for 2022, a total of $1,242,966 (2021 – $9,635,577) was operating expenses and the remainder was non-recurring expenses which included, interest expense of $83,199 (2021 – $56,732), and loss on debt extinguishment of $27,043 (2021 – nil). The operating expenses consisted principally of consulting fees in the development of the Company's cannabis business, general office expenses, professional fees and rent.

*Net Loss*

For the three-month period ended November 30, 2022, the Company had a net loss of $1,309,541 compared to a net loss of $10,068,081 for the three-month period ended November 30, 2021. This was principally related to the expenses referenced in the previous paragraph.

**Liquidity and Capital Resources**

The following table sets forth the major components of our statements and consolidated statements of cash flows for the periods presented.

---

| | | |
|:---|:---|:---|
|  | **Three Months** <br>**Ended**<br>**November 30,** <br>**2022** | **Three Months** <br>**Ended**<br>**November 30,** <br>**2021** |
| Cash used in operating activities | $(595856) | $(1715953) |
| Cash used in investing activities | $(66210) | $(375413) |
| Cash from financing activities | $717208 | $1998111 |
| Decrease in cash during the period | $55142 | $(93255) |
| Effect of exchange rate change | $(33515) | $(51041) |
| Cash, beginning of period | $96043 | $419825 |
| Cash, end of period | $117670 | $275529 |

---

As at November 30, 2022, we had working deficit of $5,813,082. Our primary cash flow needs are for the development of our cannabis products, operating costs, administrative expenses and for general working capital.

As of November 30, 2022, the Company had $1,433,441 in current assets, consisting of $117,670 in cash, $1,188,963 in inventory, $102,153 in other receivables, and $24,655 in prepaid expenses. Other assets mainly include deposits and advances of $2,854,155 (principally related to our building to be located in Nevada), property, plant and equipment of $1,397,466, right-of-use assets of $168,128 and intangible assets of $40,959.

To date, the Company has financed its operations through equity sales and through the sale of convertible notes. The Company has recently entered into an agreement with a broker-dealer to complete a public offering of shares.

*Convertible Notes during the Quarter ended November 30, 2021*

The Company has granted each and every one of the secured convertible note holders referenced below a continuing security interest in, a general lien upon, and a right of setoff against all existing and future assets and property under the terms of a security agreement.

On October 1, 2021, the Company issued a secured convertible note with a face value of $100,000. The Note bears interest at 10% per annum. The Note is due on demand after March 31, 2022 and is convertible into shares of the Company's common stock at any time prior to maturity at a conversion price of $1.25 per share. On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. On March 31, 2022, the Company entered into further amendment to the convertible note. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or before September 30, 2022 for no additional consideration.

On October 25, 2021, the Company issued a secured convertible note with a face value of $100,000. The Note bears interest at 10% per annum. The Note is due on demand after March 31, 2022 and is convertible into shares of the Company's common stock at any time prior to maturity at a conversion price of $1.25 per share. On November 1, 2021, the Company entered into amendment to the convertible note. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or before March 31, 2022 for no additional consideration. On March 31, 2022, the Company entered into further amendment to the convertible note. Pursuant to the amendment, the maturity date of the convertible note was amended to due on demand on or before September 30, 2022 for no additional consideration.

---

| |
|:---|
| 58 |
| *[Tables of Contents](#TOC)* |

---

*Convertible Notes during the Quarter ended November 30, 2022*

On November 28, 2022, the Company issued a convertible note with a face value of $100,000. The Note bears interest at 10% per annum and is due on demand after May 28, 2023. The Note is convertible into shares of the Company's common stock at any time at a conversion price equal to the lesser of 80% of the twenty-day average closing price per share (but not less than $0.20 per share) or $0.50 per share.

*Equity Transactions during the Quarter ended November 30, 2021*

On September 2, 2021, the Company issued 2,175,933 common shares at fair value of $2,447,925 on issuance date from treasury to the CFO and COO and 1,900,000 common shares at fair value of $2,137,500 to certain employees of the Company as bonuses for past services, which was expensed as consulting fees.

On September 2, 2021, the Company issued 2,997,237 common shares measured at fair value on issuance date of $3,371,892 from treasury for consulting services related to business development for a 12-month period from the issuance date.

On October 20, 2021, the Company issued 3,699,955 units at $0.75 per unit for proceeds of $2,774,966, of which $865,467 was received during the year ended August 31, 2021. Each unit consists of one common share of the Company and one warrant to purchase the Company's one common shares at $1.25 for a period of two years. In connection with the financing, the Company incurred brokerage commission fees and other share issuance costs of $210,736.

On November 5, 2021, the Company issued 905,000 units at $0.75 per unit for proceeds of $678,750. Each unit consists of one common share of the Company and one warrant to purchase the Company's one common shares at $1.25 for a period of two years. In connection with the financing, the Company issued 8,000 shares of common stock with a fair value of $6,000 as a finder's fee and incurred other finders' fees and other share issuance costs of $42,654.

On November 24, 2021, the Company issued 36,000 units at $0.75 per unit for proceeds of $27,000. Each unit consists of one common share of the Company and one warrant to purchase the Company's one common shares at $1.25 for a period of two years.

On November 30, 2021, the Company issued 8,268 shares as consideration for extending the maturity date of a convertible note.

During the three months ended November 30, 2021, the Company issued 634,667 common shares to certain investors for no consideration by error. As of November 30, 2022, the Company has cancelled 266,667 common shares and is in the process of cancelling the remaining 368,000 common shares.

*Equity Transactions during the Quarter ended November 30, 2022*

On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022.

On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred finder's fee of $10,000 and share issuance costs of $2,792.

On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606.

On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437.

***Future Financing***

In connection with its proposed business plan and currently ongoing and proposed acquisitions, in addition to the possible proceeds from this offering the Company will be required to complete substantial and significant additional capital formation. Such formation could be through additional equity offerings, debt, bank financings or a combination of any source of financing. There can be no assurance that the Company will be successful in completion of such financings.

---

| |
|:---|
| 59 |
| *[Tables of Contents](#TOC)* |

---

***Plan of Operations***

As noted above, the continuation of our current plan of operations requires us to raise significant additional capital. If we are successful in raising capital through the sale of convertible notes or common shares, we believe that we will have sufficient cash resources to fund our plan of operations through 2023. If we are unable to do so, we may have to curtail and possibly cease some operations. We intend to use the net proceeds from the offering for operating capacity in Colombia, Canada and the United States, regulatory compliance, intellectual property, working capital and general corporate purposes.

We continually evaluate our plan of operations to determine the manner in which we can most effectively utilize our limited cash resources. The timing of completion of any aspect of our plan of operations is highly dependent upon the availability of cash to implement that aspect of the plan and other factors beyond our control. There is no assurance that we will successfully obtain the required capital or revenues, or, if obtained, that the amounts will be sufficient to fund our ongoing operations.

***Capital Expenditures***

As of November 30, 2022 the company had purchased property plant and equipment of $1,397,466 and paid net cash of $2,854,155 in deposits for an asset acquisition. As of August 31, 2022 the company had purchased property plant and equipment of $1,444,038 and paid net cash of $2,869,825 in deposits for an asset acquisition.

*MediColombias Acquisition (Colombia Licensed Producer)* 

On August 29, 2019, the Company entered into a Share Purchase Agreement ("Purchase Agreement") with Dorson Commercial Corp. ("Dorson") as the sole owner of Baleno Ltd. to purchase all of the issued and outstanding shares of Baleno Ltd., the sole owner of Medicolombia Cannabis S.A.S. ("Medicolombia"). Medicolombia is based in Colombia with a full set of licenses and a lease agreement in place to begin production on a 5 hectare parcel of land. We have the ability to scale production to over hundreds of hectares. This is located in the area of Bucamaranga, Colombia.

This acquisition includes a team of experts and significant expenditures spent on an irrigation holding pond, security towers, fencing, etc. to meet the Colombia minister of justice and minister of agriculture requirements.

Pursuant to the agreement the Company acquired all of the issued and outstanding shares of Medicolombia in exchange for $700,000 and 4,500,000 shares of Allied. The Company closed and completed the acquisition on February 17, 2020. Medicolombia has subsequently changed its name to Allied Colombia S.A.S.

*Natural Health Products Acquisition* 

In May 2019 the management team of AM Biosciences were able to negotiate the inclusion of a natural health products catalogue of products. This includes 50 products in the natural health vertical market. Three of these products are of particular interest as they have Natural Health Products registration numbers with Health Canada. AM Biosciences can add these to the product offerings both in Canada and the United States.

*Xtreme Cubes Building* 

In June 2019, AM Biosciences signed the production and manufacturing contract to begin the manufacturing of the full building initially intended for the Canada extraction and production facility.

The Company determined to utilize these building assets in connection with our potential United States operations in the State of Nevada upon on the occurrence or waiver of the changes in U.S. federal law to permit the general cultivation, distribution and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the "Triggering Event"). In connection with that determination, our wholly owned subsidiary, Allied US Products LLC, a Nevada limited liability company, entered into a contingent asset purchase agreement (the "Contingent Asset Purchase Agreement") which allows for the purchase of a Nevada State US-based cannabis license from a subsidiary of Fiore Cannabis, Ltd. ("Fiore Subsidiary"). We also entered into a 25 year land lease with the Fiory Subsidiary which we intended to use for this operation.

We will only conduct business activities related to growing or processing cannabis in jurisdictions, including the United States, when it is federally permissible to do so. While we have several arrangements with United States based companies that may themselves participate in the United States cannabis market, these relationships do not violate the federal laws of the United States respecting cannabis and in no manner involve us in any activities in the United States respecting cannabis.

When complete, the building will be a fully scalable, modular building. A portion of the building was delivered to the property on the land lease. In early December 2022, the Company was advised that the Fiore Subsidiary had become insolvent and that a trustee's sale had been scheduled for the property which the Company had leased. In order to protect the Company's interests, the Company filed a complaint in the Eighth Judicial District Court in Clark County, Nevada again the Fiore Subsidiary, the creditor bringing the trustee's sale and the trustee, seeking injunctive relief to terminate the trustee's sale or alternatively money damages. The Company filed a lis pendens against the property to reflect this complaint and to protect its interests in the building. The Trustee's sale went forward and the successful bidder was the underlying creditor. Subsequently the Company has been amicably working with that bidder to enable return of the building and equipment on the property.

---

| |
|:---|
| 60 |
| *[Tables of Contents](#TOC)* |

---

The Company made an upfront payment of $230,000 USD in June 2019, an additional payment of $903,385 in August 2019 and an additional payment of$92,000 in March 2020. At November 30, 2022, Company had deposits of $2,656,695 (August 31, 2022 - $2,656,695) to purchase prefabricated buildings. As of November 30, 2022, the building had not yet been fully delivered and the amounts have been recorded as deposits.

***Commitments and Contractual Obligations***

As a "smaller reporting company" as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

***Off-balance Sheet Arrangements***

The Company has no off-balance sheet arrangements.

***Going Concern***

As reflected in the accompanying financial statements, the Company had an accumulated deficit of $36,242,206 at November 30, 2022 and a net loss of $1,309,541 for the three months ended November 30, 2022.

The Company does not yet have a history of financial stability. Historically, the principal source of liquidity has been the issuance of convertible notes and equity securities. In addition, the Company has generated no revenues since inception. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The ability of the Company to continue operations is dependent on the success of Management's plans, which include the raising of capital through the issuance of equity securities, until such time that funds provided by operations are sufficient to fund working capital requirements.

The Company will require additional funding to finance the growth of its current and expected future operations as well as to achieve its strategic objectives. The Company believes its current available cash will be sufficient to meet its cash needs for the near future. There can be no assurance that financing will be available in amounts or terms acceptable to the Company, if at all.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

**Item 4. Controls and Procedures.**

**Disclosure Controls and Procedures**

***Evaluation of Disclosure Controls and Procedures***

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the Chief Financial Officer and Chief Executive Officer concluded that our disclosure controls and procedures were effective.

***Changes in Internal Control over Financial Reporting****.*

As a result of accounting issues in Colombia, we have engaged new accounting personnel in Colombia to improve our accounting and controls and procedures in that segment of our operations. There were no other changes in our internal control over financial reporting that occurred during the period from August 31, 2022 through November 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

---

| |
|:---|
| 61 |
| *[Tables of Contents](#TOC)* |

---

**PART II—OTHER INFORMATION**

**Item 1. Legal Proceedings.**

In June 2019, AM Biosciences signed the production and manufacturing contract to begin the manufacturing of the full building initially intended for the Canada extraction and production facility.

The Company had determined to utilize these building assets in connection with our potential United States operations in the State of Nevada upon on the occurrence or waiver of the changes in U.S. federal law to permit the general cultivation, distribution and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the "Triggering Event"). In connection with that determination, our wholly owned subsidiary, Allied US Products LLC, a Nevada limited liability company, entered into a contingent asset purchase agreement (the " Contingent Asset Purchase Agreement") which allows for the purchase of a Nevada State US-based cannabis license from a subsidiary of Fiore Cannabis, Ltd. ("Fiore Subsidiary"). We also entered into a 25 year land lease with the Fiory Subsidiary which we intended to use for this operation.

We will only conduct business activities related to growing or processing cannabis in jurisdictions, including the United States, when it is federally permissible to do so. While we have several arrangements with United States based companies that may themselves participate in the United States cannabis market, these relationships do not violate the federal laws of the United States respecting cannabis and in no manner involve us in any activities in the United States respecting cannabis.

When complete, the building will be a fully scalable, modular building. A portion of the building was delivered to the property on the land lease. In early December 2022, the Company was advised that the Fiore Subsidiary had become insolvent and that a trustee's sale had been scheduled for the property which the Company had leased. In order to protect the Company's interests, the Company filed a complaint in the Eighth Judicial District Court in Clark County, Nevada again the Fiore Subsidiary, the creditor bringing the trustee's sale and the trustee, seeking injunctive relief to terminate the trustee's sale or alternatively money damages. The Company filed a lis pendens against the property to reflect this complaint and to protect its interests in the building. The Trustee's sale went forward and the successful bidder was the underlying creditor. Subsequently the Company has been amicably working with that bidder to enable return of the building and equipment on the property.

We are not aware of any other legal proceedings contemplated by any governmental authority or any other party involving us or our properties,

As of the date of this report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. We are not aware of any other legal proceedings pending or that have been threatened against us or our properties.

From time to time the Company may be named in claims arising in the ordinary course of business. Currently, no legal proceedings or claims, other than those disclosed above, are pending against or involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on its business and financial condition.

As of the date of this report, no director, officer or affiliate is (i) a party adverse to us in any legal proceeding, or (ii) has an adverse interest to us in any legal proceedings. We are not aware of any other legal proceedings pending or that have been threatened against us or our properties.

From time to time the Company may be named in claims arising in the ordinary course of business. Currently, no legal proceedings or claims, other than those disclosed above, are pending against or involve the Company that, in the opinion of management, could reasonably be expected to have a material adverse effect on its business and financial condition.

**Item 1A. Risk Factors.**

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

---

| |
|:---|
| 62 |
| *[Tables of Contents](#TOC)* |

---

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

On September 21, 2022, the Company issued 1,350,000 shares of common stock at $0.40 per share for $540,000 subscriptions received during the year ended August 31, 2022.

On October 7, 2022, the Company issued 1,575,000 shares of common stock at $0.40 per share for proceeds of $630,000. In connection with the financing, the Company incurred finder's fee of $10,000 and share issuance costs of $2,792.

On October 7, 2022, the Company issued 75,000 shares of common stock with a fair value of $44,606 to settle related party accounts payable of $30,000, resulting in a loss on settlement of $14,606.

On October 7, 2022, the Company issued 70,560 shares of common stock with a fair value of $41,966 to settle $29,529 in debt, resulting in a loss on settlement of $12,437.

**Item 3. Defaults Upon Senior Securities.**

None

**Item 4. Mine Safety Disclosures**

None

**Item 5. Other Information.**

**Not applicable**

---

| |
|:---|
| 63 |
| *[Tables of Contents](#TOC)* |

---

**SIGNATURES\***

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Allied Corp.** | **Allied Corp.** |
|  | (Registrant) | (Registrant) |
| Date: February 14, 2023 | By: | */s/ Calum Hughes* |
|  |  | Calum Hughes |
|  |  | Chief Executive Officer and<br>Director {Principal and Executive Officer} |
| Date: February 14, 2023 | By: | */s/ Ryan Maarschalk* |
|  |  | Ryan Maarschalk |
|  |  | Chief Financial Officer |
|  |  | (Principal Financial Officer<br>Principal Accounting Officer) |

---

## Exhibit 31.1

**EXHIBIT 31.1**

**CERTIFICATIONS**

I, Calum Hughes, principal executive officer, certify that:

1. I have reviewed this quarterly report of Allied Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and,

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | */s/ Calum Hughes* |
|  |  | Calum Hughes |
|  |  | Chief Executive Officer and<br> Director (Principal Executive Officer) |

---

## Exhibit 31.2

**EXHIBIT 31.2**

**CERTIFICATIONS**

I, Ryan Maarschalk, principal accounting officer, certify that:

1. I have reviewed this quarterly report of Allied Corp.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d – 15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and,

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | */s/ Ryan Maarschalk* |
|  |  | Ryan Maarschalk |
|  |  | Chief Financial Officer, |
|  |  | (Principal Financial Officer) |

---

## Exhibit 32.1

**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended November 30, 2022 of Allied Corp., a Nevada corporation (the "Company"), as filed with the Securities and Exchange Commission on the date hereof (the "Quarterly Report"), I, Calum Hughes, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Quarterly Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in this Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | */s/ Calum Hughes* |
|  |  | Calum Hughes |
|  |  | Chief Executive Officer and Director |

---

## Exhibit 32.2

**EXHIBIT 32.2**

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended November 30, 2022 of Allied Corp., a Nevada corporation (the "Company"), as filed with the Securities and Exchange Commission on the date hereof (the "Quarterly Report"), I, Ryan Maarschalk, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Quarterly Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in this Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

---

| | | |
|:---|:---|:---|
| Date: February 14, 2023 | By: | */s/ Ryan Maarschalk* |
|  |  | Ryan Maarschalk |
|  |  | Chief Financial Officer, |
|  |  | (Principal Financial Officer) |

---